Title: SUBSTITUTED PYRAZOLOPYRIMIDINES AS AKT KINASE INHIBITORS

Abstract: Compounds of formula (I) which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
The invention relates to substituted Pyrazolopyrimidine compounds, a process for their production and the use thereof.

Known technical background

Cancer is the second most prevalent cause of death in the United States, causing 450,000 deaths per year. While substantial progress has been made in identifying some of the likely environmental and hereditary causes of cancer, there is a need for additional therapeutic modalities that target cancer and related diseases. In particular there is a need for therapeutic methods for treating diseases associated with dysregulated growth / proliferation.

Cancer is a complex disease arising after a selection process for cells with acquired functional capabilities like enhanced survival / resistance towards apoptosis and a limitless proliferative potential. Thus, it is preferred to develop drugs for cancer therapy addressing distinct features of established tumors.

One pathway that has been shown to mediate important survival signals for mammalian cells comprises receptor tyrosine kinases like platelet-derived growth factor receptor (PDGF-R), human epidermal growth factor 2/3 receptor (HER2/3), or the insulin-like growth factor 1 receptor (IGF-1R). After activation the respective by ligand, these receptors activate the phoshatidylinositol 3-kinase (PI3K)/Akt pathway. The phoshatidylinositol 3-kinase (PI3K)/Akt protein kinase pathway is central to the control of cell growth, proliferation and survival, driving progression of tumors. Therefore within the class of serine-threonine specific signalling kinases, Akt (protein kinase B; PKB) with the isoenzymes Akt1 (PKBa), Akt2 (PKB β), and Akt3 (PKB γ) is of high interest for therapeutic intervention. Akt is mainly activated in a PI3-kinase dependent manner and the activation is regulated through the tumor suppressor PTEN (phosphatase and tensin homolog), which works essentially as the functional antagonist of PI3K.
The PI3K/Akt pathway regulates fundamental cellular functions (e.g. transcription, translation, growth and survival), and is implicated in human diseases including diabetes and cancer. The pathway is frequently overactivated in a wide range of tumor entities like breast and prostate carcinomas. Upregulation can be due to overexpression or constitutively activation of receptor tyrosine kinases (e.g. EGFR, HER2/3), which are upstream and involved in its direct activation, or gain- or loss-of-function mutants of some of the components like loss of PTEN. The pathway is targeted by genomic alterations including mutation, amplification and rearrangement more frequently than any other pathway in human cancer, with the possible exception of the p53 and retinoblastoma pathways. The alterations of the PI3K/Akt pathway trigger a cascade of biological events, that drive tumor progression, survival, angiogenesis and metastasis. Activation of Akt kinases promotes increased nutrient uptake, converting cells to a glucose-dependent metabolism that redirects lipid precursors and amino acids to anabolic processes that support cell growth and proliferation. These metabolic phenotype with overactivated Akt lead to malignancies that display a metabolic conversion to aerobic glycolysis (the Warburg effect). In that respect the PI3K/Akt pathway is discussed to be central for survival despite unfavourable growth conditions such as glucose depletion or hypoxia.

A further aspect of the activated PI3K/Akt pathway is to protect cells from programmed cell death ("apoptosis") and is hence considered to transduce a survival signal. By acting as a modulator of anti-apoptotic signalling in tumor cells, the PI3K/Akt pathway, particular Akt itself is a target for cancer therapy. Activated Akt phosphorylates and regulates several targets, e.g. BAD, GSK3 or FKHRL1, that affect different signalling pathways like cell survival, protein synthesis or cell movement. This PI3K/Akt pathway also plays a major part in resistance of tumor cells to conventional anti-cancer therapies. Blocking the PI3K/Akt pathway could therefore simultaneously inhibit the proliferation of tumor cells (e.g. via the inhibition of the metabolic effect) and sensitize towards pro-apoptotic agents.

Akt inhibition selectively sensitized tumor cells to apoptotic stimuli like Trail, Campthothecin and Doxorubicin. Dependent on the genetic background / molecular apparitions of tumors, Akt inhibitors might induce apoptotic cell death in monotherapy as well.
From WO 2008/070016 tricyclic Akt inhibitors are known which are alleged to be unspecific Akt kinase inhibitors. No data for any specific compounds are disclosed. Different Akt inhibitors are disclosed in WO 2009/021990, WO201 00881 77, WO2010104705 , WO20101 14780 , WO201 1033265 , WO201 10551 15. In a recent disclosure, Y. Li et al (Bioorg. Med. Chem. Lett. 2009, 19, 834-836 and cited references therein) detail the difficulty in finding optimal Akt inhibitors. The potential application of Akt inhibitors in multiple disease settings, such as for example, cancer, makes the provision of new Akt inhibitors still highly desirable.

Description of the invention

A solution to the above problem is the provision of improved Akt inhibitors, whereby the current compounds have an improved pharmacokinetic profile. It has now been found that the new substituted Pyrazolopyrimidine compounds, which are described in detail below, are Akt inhibitors with an improved pharmacokinetic profile.

In accordance with a first aspect, the invention relates to compounds of formula (I) according to claim 1

![Chemical Structure](image)

in which

- $R^1$ is hydrogen, a 1-6C-alkyl group,
- wherein said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, $-\text{NR}^7\text{R}^8$, $-\text{NR}^7\text{R}^8$,
cyano, (=0), -C(0)NR \textit{R}^8, -C(0)OR \textit{R}^9, -NHC(0)\textit{R}^\textit{\theta}, -NHS(0)_2\textit{R}^\textit{\theta},
heteroaryl,
\textit{R}^2 \text{ is hydrogen or a 1-6C-alkyl group}
wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:
hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, -NR\textit{R}^8, cyano, -C(0)NR \textit{R}^8, -C(0)OR \textit{R}^9, -NHC(0)\textit{R}^\textit{\theta}, -NHS(0)_2\textit{R}^\textit{\theta},
-NH-(1-6C-alkylen>-0-(1-6C-alkyl),
\textit{R}^3 \text{ is hydrogen, 1-6C-alkyl which is optionally substituted one or more times with halogen,}
\textit{R}^4 \text{ is phenyl optionally substituted by 1-6C-alkyl, halogen, cyano,}
\textit{R}^5 \text{ is hydrogen, halogen,}
\textit{R}^6 \text{ is hydrogen, 1-6C-alkyl,}
\textit{X} \text{ is } -\text{CH}_2-,\text{ -CH(OH)-,}
\textit{Y} \text{ is } -\text{CH}_2-,\text{ -CH(OH)-,}
\textit{R}^7, \textit{R}^8 \text{ which can be the same or different, is hydrogen, hydroxy, 3-7C-cycloalkyl or a group selected from 1-4C-alkyl, 1-6C-alkoxy, wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:}
halogen, hydroxy, mono- or di-(1-4C-alkylamino), 1-4C-alkoxy, or 3-7C-cycloalkyl or,
\textit{R}^7 \text{ and } \textit{R}^8 \text{ together with the nitrogen to which they are attached may also form a saturated or unsaturated 3-6C-heterocyclic ring,}
which is optionally substituted by (=0)
\textit{R}^9 \text{ is hydrogen, 1-6C-alkyl,}
\textit{R}^{10} \text{ is } 1-4C-alkyl \text{ (optionally substituted in the same way of differently one or more times with halogen, hydroxy) or 3-7C-cycloalkyl, or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.}

Another aspect of the present invention are compounds of formula (I) according to claim 1 wherein
wherein
R\(^1\) is hydrogen, a 1-6C-alkyl group,
wherein said group being optionally substituted, one or more times with halogen,
R\(^2\) is hydrogen,
R\(^3\) is hydrogen, a 1-6C-alkyl group,
wherein said group being optionally substituted, one or more times with halogen,
R\(^4\) is phenyl optionally substituted by 1-6C-alkyl, halogen, cyano,
R\(^5\) is hydrogen,
R\(^6\) is hydrogen,
X is -CH\(_2\)-,
Y is -CH\(_2\)-, -CH(OH)-,
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of
said N-oxide, tautomer or stereoisomer.

A further aspect of the present invention are compounds of formula (I) according to
claim 1 wherein
R\(^1\) is hydrogen, a 1-3C-alkyl group,
wherein said group being optionally substituted, one or more times with halogen,
R\(^2\) is hydrogen,
R\(^3\) is hydrogen, a 1-3C-alkyl group,
wherein said group being optionally substituted, one or more times with halogen,
R\(^4\) is phenyl
R\(^5\) is hydrogen,
R\(^6\) is hydrogen,
X is -CH\(_2\)-,
Y is -CH\(_2\)-,
or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of
said N-oxide, tautomer or stereoisomer.
Another aspect of the present invention are compounds of formula (I) according to claim 1 wherein:

- \( R^1 \) is hydrogen, **1-3C-alkyl** optionally substituted with fluorine,
- \( R^2 \) is hydrogen,
- \( R^3 \) is hydrogen or **1-3C-alkyl** optionally substituted with fluorine,
- \( R^4 \) is phenyl,
- \( R^5 \) is hydrogen,
- \( R^6 \) is hydrogen,
- \( X \) is -CH₂⁻,
- \( Y \) is -CH₂⁻,

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

A further aspect of the present invention are compounds of formula (I) according to claim 1 which are selected from the group consisting of:

1. \( 1\text{-}[4\text{-}\{5,7\text{-Dimethyl}\text{-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl\}phenyl}\text{cyclobutanamine} \),
2. \( 1\text{-}[3\text{-Phenyl}\text{-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl]phenyl}\text{cyclobutanamine} \).

One aspect of the invention are compounds of formula (I) as described in the examples as characterized by their names in the title as claimed in claim 5 and their structures as well as the subcombinations of all residues specifically disclosed in the compounds of the examples.

One aspect of the present invention are the compounds disclosed in the examples as well as the intermediates as used for their synthesis.

One aspect of the invention is intermediate (II) as defined below in the process section.

If embodiments of the invention as disclosed herein relate to compounds of formula (I), it is understood that those embodiments refer to the compounds of formula (I) as disclosed in the claims and the examples.
Another aspect of the Invention are compounds of formula (I), wherein
R1 is 1-3C-alkyl or 1-3C-alkyl substituted with halogen, preferably substituted with fluorine.

Another aspect of the invention are compounds of formula (I), wherein
R1 is 1-3C-alkyl or CF3.

Another aspect of the Invention are compounds of formula (I), wherein
R1 is methyl, ethyl, or CF3.

Another aspect of the Invention are compounds of formula (I), wherein
R2 is hydrogen, 1-6C-alkyl, 1-6C-alkoxy, halogen, cyano, CO(NR7R8), aryl, heteroaryl,
wherein said 1-6C-alkyl, 1-6C-alkoxy, aryl, heteroaryl is optionally substituted, one or more times, identically or differently, with a substituent selected from:
hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, -NR7R8, cyano,-
C(0)NR7R8, -C(0)OR9, -NHC(0)R10, -NHS(0)2R10.

Another aspect of the Invention are compounds of formula (I), wherein
R2 is hydrogen.

Another aspect of the invention are compounds of formula (I), wherein
R3 is 1-3C-alkyl or 1-3C-alkyl substituted with halogen, preferably substituted with fluorine.

Another aspect of the invention are compounds of formula (I), wherein
R3 is 1-3C-alkyl or CF3.

Another aspect of the invention are compounds of formula (I), wherein
R3 is methyl, ethyl, or CF3.
Another aspect of the invention are compounds of formula (I), wherein $R^1$ and $R^3$ are substituted identically.

Another aspect of the invention are compounds of formula (I), wherein $R^4$ is phenyl.

A further aspect of the invention are compounds of formula (I), wherein $Y = \text{-Obta-}$

In a further embodiment of the above-mentioned aspects, the invention relates to compounds of formula (I), wherein $R^6$ is hydrogen and $R^5$ is hydrogen.

In another embodiment of the above-mentioned aspects, the invention relates to compounds of formula (I), wherein $R^2$, $R^5$ and $R^6$ is hydrogen, and $R^4$ is unsubstituted phenyl.

In a further embodiment of the above-mentioned aspects, the invention relates to compounds of formula (I), wherein $R^5$ is hydrogen and $R^4$ is unsubstituted phenyl.

Another embodiment of the invention are the compounds of the claims as disclosed in the claims section wherein the definitions are limited according to the preferred or more preferred definitions as disclosed below or specifically disclosed residues of the exemplified compounds and subcombinations thereof.

**Definitions**

Unless defined otherwise in the claims the constituents defined below can optionally be substituted, one or more times, identically or differently, with a substituent selected from:

- hydroxy, halogen, cyano, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, $-\text{NR}_7\text{R}_8$, cyano, $(-0)$, $-\text{C}(0)\text{NR}_7\text{R}_8$, $-\text{C}(0)\text{OR}_9$, $-\text{NHC}(0)\text{R}_{10}$, $-\text{NHS}(0)\text{R}_{10}$. An alkyl constituent be-
ing substituted more times by halogen includes also a completely halogenated alkyl moiety such as e.g. CF₃.

Should a constituent be composed of more than one part, e.g. -0-(1-6Calkyl)-3-7C-cycloalkyl, the position of a possible substituent can be at any of these parts at any suitable position. A hyphen at the beginning of the constituent marks the point of attachment to the rest of the molecule. Should a ring be substituted the substituted could be at any suitable position of the ring, also on a ring nitrogen atom.

The term "comprising" when used in the specification includes "consisting of.

If it is referred to "as mentioned above" or "mentioned above" within the description it is referred to any of the disclosures made within the specification in any of the preceding pages.

"suitable" within the sense of the invention means chemically possible to be made by methods within the knowledge of a skilled person.

"1-6C-alkyl" is a straight-chain or branched alkyl group having 1 to 6 carbon atoms. Examples are methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl and tert-butyl, pentyl, hexyl, preferably 1-4 carbon atoms (1-4C-alkyl), more preferably 1-3 carbon atoms (1-3C-alkyl). Other alkyl constituents mentioned herein having another number of carbon atoms shall be defined as mentioned above taking into account the different length of their chain. Those parts of constituents containing an alkyl chain as a bridging moiety between two other parts of the constituent which usually is called an "alkylene" moiety is defined in line with the definition for alkyl above including the preferred length of the chain e.g. methylen, ethylene, n-propylen, iso-propylen, n-butylen, isobutylen, tert-butylen.

"Halogen" within the meaning of the present invention is iodine, bromine, chlorine or fluorine, preferably "halogen" within the meaning of the present invention is chlorine or fluorine, should a halogen atom be needed as leaving group within the synthesis iodine or bromine are preferred.
"1-4C-Haloalkyl" is a straight-chain or branched alkyl group having 1 to 4 carbon atoms in which at least one hydrogen is substituted by a halogen atom. Examples are chloromethyl or 2-bromoethyl. For a partially or completely fluorinated C1-C4-alkyl group, the following partially or completely fluorinated groups are considered, for example: fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, 1,1-difluoroethyl, 1,2-difluoroethyl, 1,1,1-trifluoroethyl, tetrafluoroethyl, and pentafluoroethyl, whereby fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, 1,1-difluoroethyl, or 1,1,1-trifluoroethyl are preferred. Partially or completely fluorinated C1-C4-alkyl groups are considered to be encompassed by the term 1-4C-haloalkyl.

"1-6C-Alkoxy" represents radicals, which in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 6 carbon atoms. Examples which may be mentioned are the hexoxy, pentoxy, butoxy, iso-butoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy, ethoxy and methoxy radicals, preferred are methoxy, ethoxy, propoxy, isopropoxy.

"3-7C-Heterocyclyl", or "heterocyclyl" represents a mono- or polycyclic, preferably mono- or bicyclic, more preferably monocyclic, nonaromatic heterocyclic radical containing, 4 to 10, preferably 4 to 7, ring atoms, and up to 3, preferably up to 2, hetero atoms and/or hetero groups from the series consisting of N, O, S, SO, SO2. The heterocyclyl radicals can be saturated or partially unsaturated and, unless stated otherwise, may be optionally substituted, one or more times, identically or differently, with a substituent selected from: 1-4C-alkyl, 1-4C-haloalkyl, 1-4C-alkoxy, hydroxy, fluorine or (=0) whereby the 1-4C-alkyl may be optionally further substituted with hydroxy and the double bonded oxygen atom leads to a carbonyl group together with the carbon atom of the heterocyclyl ring at any suitable position. Particularly preferred heterocyclic radicals are 4- to 7-membered monocyclic saturated heterocyclyl radicals having up to two hetero atoms from the series consisting of O, N and S. The following may be mentioned by way of example and by preference: oxetanyl, tetrahydrofuranyl, azetidinyl, 3-hydroxyazetidinyl, 3-fluoroazetidinyl, 3,3-difluoroazetidinyl, pyrrolidinyl, 3-hydroxypyrrolidinyl, pyrrolinyl,
piperidinyl, 3-hydroxypiperidinyl, 4-hydroxypiperidinyl, 3-fluoropiperidinyl, 3,3-
difluoropiperidinyl, 4-fluoropiperidinyl, 4,4-difluoropiperidinyl, piperazinyl, N-methyl-
piperazinyl, N-(2-hydroxyethyl)-piperazinyl, morpholinyl, thiomorpholinyl, azepanyl,
homopiperazinyl, N-methyl-homopiperazinyl.

In the case of \(-\text{NR}^7\text{R}^8\), when \text{R}^7 and \text{R}^8 together with the nitrogen atom to which
they are attached form a 3-6C-heterocyclic ring, the term "3-6C-heterocyclic ring"
includes all saturated or unsaturated non-arylic heterocyclic rings containing 4 to 7
ring atoms and having 1 or 2 nitrogen atoms, or 1 nitrogen atom and 1 oxygen atom.
The 3-6C-heterocyclic ring may be optionally substituted one or more times,
identically or differently, with a substituent selected from: 1-4C-alkyl, 1-4C-
haloalkyl, 1-4C-alkoxy, hydroxy, fluorine, or (=0) - an oxygen atom being connected via a
double bond to a carbon atom of the ring thus forming a carbonyl group which can be positioned besides the nitrogen atom resulting in a lactame moiety or at any other carbon atom of the ring, whereby the 1-4C-alkyl may be
optionally further substituted with hydroxy. Preferred examples are azetidine, 3-
hydroxyazetidine, 3-fluoroazetidine, 3,3-difluoroazetidine, pyrrolidine, pyrroldinetone,
3-hydroxypyrrolidine, piperidine, 3-hydroxypiperidine, 4-hydroxypiperidine, 3-
fluoropiperidine, 3,3-difluoropiperidine, 4-fluoropiperidine, 4,4-difluoropiperidine,
1H-pyridine-2-one, piperazine, N-methyl-piperazine, N-(2-hydroxyethyl)-
piperazine, morpholine.

"Aryl" represents a mono-, or bicyclic aromatic carbocyclic radical having, as a rule, 6 to 10 carbon atoms; by way of example phenyl or naphthyl. Phenyl is preferred. The aryl moiety can be substituted one or more times, identically or differently by hydroxy, halogen, cyano, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, \text{-NR}^7\text{R}^8,
cyano, \text{-C(0)NR}^7\text{R}^8, \text{-C(0)OR}^9, \text{-NHC(0)R}^{10}, \text{-NHS(0)}_\text{2R}^{10}$. In one embodiment of the Invention if the phenyl moiety were a substituted it is not substituted or only substituted once.

The term "heteroaryl" represents a monocyclic 5- or 6-membered aromatic
heterocycle or a fused bicyclic aromatic moiety comprising without being
restricted thereto, the 5-membered heteroaryl radicals furyl, thieryl, pyrryl, oxo-
zolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl (1,2,4-triazolyl, 1,3,4-triazolyl or 1,2,3-triazolyl), thiadiazoyl (1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl or 1,2,4-thiadiazolyl) and oxadiazoyl (1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl or 1,3,4-oxadiazolyl or 1,2,4-oxadiazolyl), as well as the 6-membered heteroaryl radicals pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl as well as the fused ring systems such as e.g. phthalidyl-, thiophthalidyl-, indolyl-, isoindolyl-, dihydroindolyl-, dihydroisoindolyl-, indazolyl-, benzothiazolyl-, benzoindolyl-, benzimidazolyl-, benzoxazinonyl-, chinolinyli-, isoquinolinyli-, chinazolinyli-, chinoxalinyli-, cinnolinyli-, phthalazinyl-, furanopyridyl-, furanopyrimidinyl-, furanopyridazinyl-, as well as the 6-membered heteroaryl radicals pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl as well as the fused ring systems such as e.g. phthalidyl-, thiophthalidyl-, indolyl-, isoindolyl-, dihydroindolyl-, dihydroisoindolyl-, indazolyl-, benzothiazolyl-, benzoindolyl-, benzimidazolyl-, benzoxazinonyl-, chinolinyli-, isoquinolinyli-, chinazolinyli-, chinoxalinyli-, cinnolinyli-, phthalazinyl-, furanopyridyl-, furanopyrimidinyl-, furanopyridazinyl-, preferred fused ring system is indazolyl. Preferred 5- or 6-membered heteroaryl radicals are furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl. More preferred 5- or 6-membered heteroaryl radicals are furan-2-yl, thien-2-yl, pyrrol-2-yl, thiazolyl, oxazolyl, 1,3,4-thiadiazolyl, 1,3,4-oxadiazolyl, pyridin-2-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl or pyridazin-3-yl.

The N\(_R^7\)R\(_8^8\) group includes, for example, NH\(_2\), N(H)CH\(_3\), N(CH\(_3\))\(_2\), N(H)CH\(_3\)CH\(_3\) and N(CH\(_3\))CH\(_2\)CH\(_3\). In the case of -NR\(_7^7R^8^8\), when R\(_7^7\) and R\(_8^8\) together with the nitrogen atom to which they are attached form a 3-6C-heterocyclic ring, the term "3-6C-heterocyclic ring" is defined above. Especially preferred are pyrrolidin-2-one, 1H-pyridine-2-one.

The NH(CO)R\(_{10}^1\) group includes for example NH(CO)CH\(_3\), NH(CO)C\(_2\)H\(_5\), NH(CO)C\(_3\)H\(_7\), NH(CO)CH(CH\(_3\))\(_2\).

The NHS(O)2R\(_{10}^0\) group includes for example NHS(0)2CH\(_3\), NHS(0)2C2H\(_5\), NHS(0)\(_2\)C\(_2\)H\(_7\), NHS(0)\(_2\)CH(CH\(_3\))\(_2\).

The C(0)NR\(_7^7\)R\(_8^8\) group includes, for example, C(0)NH \(_2\), C(0)N(H)CH\(_3\), C(0)N(CH\(_3\))\(_2\), C(0)N(H)CH\(_3\)CH\(_3\), C(0)N(CH\(_3\))\(_2\)CH\(_3\) or C(0)N(CH\(_3\))\(_2\)CH\(_3\). In the case of -NR\(_7^7R^8^8\), when R\(_7^7\) and R\(_8^8\) together with the nitrogen atom to which they are
attached form a 3-6C-heterocyclic ring, the term "3-6C-heterocyclic ring" is defined above.

The C(0)OR\textsubscript{9} group includes for example C(0)OH, C(0)OCH\textsubscript{3}, C(0)OC\textsubscript{2}H\textsubscript{5}, C(0)C\textsubscript{3}H\textsubscript{7}, C(0)CH(CH\textsubscript{3})\textsubscript{2}, C(0)OC\textsubscript{6}H\textsubscript{5}, C(0)OC\textsubscript{10}H\textsubscript{n}; for C(0)0(1-6Calkyl) the alkyl part may be straight or branched.

In general and unless otherwise mentioned, the heteroarylic or heteroarylenic radicals include all the possible isomeric forms thereof, e.g. the positional isomers thereof. Thus, for some illustrative non-restricting example, the term pyridinyl or pyridinylene includes pyridin-2-yl, pyridin-2-ylen, pyridin-3-yl, pyridin-3-ylen, pyridin-4-yl and pyridin-4-ylen; or the term thienyl orthienylene includes thien-2-yl, thien-2-ylen, thien-3-yl and thien-3-ylen.

Constituents which are optionally substituted as stated herein, may be substituted, unless otherwise noted, one or more times, independently from one another at any possible position. When any variable occurs more than one time in any constituent, each definition is independent.

In case of R\textsuperscript{1} or R\textsuperscript{2} it is understood that the groups selected from 1-6C-alkyl, 1-6C-alkoxy, may be optionally substituted, one or more times, identically or differently, with a substituent selected from: hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, -NR\textsuperscript{7}R\textsuperscript{8}, cyano, (=O), -C(0)NR\textsuperscript{7}R\textsuperscript{8}, -C(0)OR\textsuperscript{9}, -NHC(0)R\textsuperscript{10}, -NHS(0)\textsubscript{2}R\textsuperscript{10}, heteroaryl. Preferably the groups -(1-6C-alkyl)-aryl, -(1-6C-alkyl)-heteroaryl, -0-(1-6C-alkyl)-heteroaryl, -0-(1-6C-alkylen)-(3-7C-cycloalkyl), -0-(1-6C-alkyl)-(3-7C-heterocyclyl), -0-(1-6C-alkyl)-aryl -0-(1 -6C-alkyl)-heteroaryl are either not substituted within the 1-6C-alkyl part, or the 1-6C-alkyl part is optionally substituted with one or two fluorine atoms.

The heteroarylic, heteroarylenic, or heterocyclic groups mentioned herein may be substituted by their given substituents or parent molecular groups, unless otherwise noted, at any possible position, such as e.g. at any substitutable ring
carbon or ring nitrogen atom. Analogously it is being understood that it is possible for any heteroaryl or heterocyclyl group to be attached to the rest of the molecule via any suitable atom if chemically suitable. Unless otherwise noted, any heteroatom of a heteroaryl or heterocyclyl ring with unsatisfied valences mentioned herein is assumed to have the hydrogen atom(s) to satisfy the valences. Unless otherwise noted, rings containing quaternizable amino- or iminotype ring nitrogen atoms (-N=) may be preferably not quaternized on these amino- or imino-type ring nitrogen atoms by the mentioned substituents or parent molecular groups.

In the context of the properties of the compounds of the present invention the term "pharmacokinetic profile" means one single parameter or a combination thereof including permeability, bioavailability, exposure, and pharmacodynamic parameters such as duration, or magnitude of pharmacological effect, as measured in a suitable experiment. Compounds with improved pharmacokinetic profiles can, for example, be used in lower doses to achieve the same effect, may achieve a longer duration of action, or a may achieve a combination of both effects.

Salts of the compounds according to the invention include all inorganic and organic acid addition salts and salts with bases, especially all pharmaceutically acceptable inorganic and organic acid addition salts and salts with bases, particularly all pharmaceutically acceptable inorganic and organic acid addition salts and salts with bases customarily used in pharmacy.

One aspect of the invention are salts of the compounds according to the invention including all inorganic and organic acid addition salts, especially all pharmaceutically acceptable inorganic and organic acid addition salts, particularly all pharmaceutically acceptable inorganic and organic acid addition salts customarily used in pharmacy. Another aspect of the invention are the salts with di- and tricarboxylic acids.

Examples of acid addition salts include, but are not limited to, hydrochlorides, hydrobromides, phosphates, nitrates, sulfates, salts of sulfamic acid, formates,
acetates, propionates, citrates, D-glucconates, benzoates, 2-(4-hydroxybenzoyl)-benzoates, butyrates, salicylates, sulfosalicylates, lactates, maleates, laurates, malates, fumarates, succinates, oxalates, malonates, pyruvates, acetoacetates, tartarates, stearates, benzensulfonates, toluenesulfonates, methanesulfonates, trifluoromethansulfonates, 3-hydroxy-2-naphthoates, benzenesulfonates, naphthalenedisulfonates and trifluoroacetates.

Examples of salts with bases include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, meglumine, ammonium, salts optionally derived from NH$_3$ or organic amines having from 1 to 16 C-atoms such as e.g. ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethyldiamine, N-methylpiperindine and and guanidinium salts.

The salts include water-insoluble and, particularly, water-soluble salts.

According to the person skilled in the art the compounds of formula (I) according to this invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula (I) according to this invention as well as all solvates and in particular all hydrates of the salts of the compounds of formula (I) according to this invention.

The term "combination" in the present invention is used as known to persons skilled in the art and may be present as a fixed combination, a non-fixed combination or kit-of-parts.

A "fixed combination" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present together in one unit dosage or in a single entity. One example of a "fixed combination" is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient
are present in admixture for simultaneous administration, such as in a formulation. Another example of a "fixed combination" is a pharmaceutical combination wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.

A non-fixed combination or "kit-of-parts" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the said first active ingredient and the said second active ingredient are present separately. The components of the non-fixed combination or kit-of-parts may be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.

The term "(chemotherapeutic) anti-cancer agents", includes but is not limited to 131 1-chTNT, abarelix, abiraterone, aclacinomycin, aclacinomycin, alemtuzumab, alitretinoin, altretamin, aminoglutethimide, amrubicin, amscarine, anastrozole, arglabin, arsenic trioxide, asparaginase, azacitidine, basiliximab, BAY 80-6946, BAY 1000394, belotecan, bendamustine, bevacizumab, bexarotene, bicalutamide, biseantrene, bleomycin, bortezomib, buserelin, busulfan, cabazitaxel, calcium folinate, calcium levofolinate, capecitabine, carboplatin, carmofur, carmustine, catumaxomab, celecoxib, cemoleukin, cetuximab, chlorambucil, chloromadinone, chloromethine, cisplatin, cladribine, cladranic acid, clofarabine, crisantaspase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dacitomycin, darbepoetin alfa, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, deslorelin, dibrospidium chloride, docetaxel, doxifluridine, doxorubicin + estrone, eculizumab, edrecolomab, elliptinium acetate, eltrombopag, endostatin, enocitabine, epirubicin, epilostanol, epoetin alfa, epoetin beta, etaplatin, eribulin, eriotinib, estradiol, estramustine, etoposide, everolimus, exemestane, fadrozole, filgrastim, fludarabine, fluorouracil, flutamide, formestane, fotemustine, fulvestrant, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, glutoxim, goserelin, histamine dihydrochloride, histrelin, hydroxy carbamidom, 1-125 seeds, ibandronic acid, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib, imiquimod, improsul-
fan, interferon alfa, interferon beta, interferon gamma, ipilimumab, irinotecan, ixabepilone, lanreotide, lapatinib, lenalidomide, lenograsitam, ientinan, ietrozole, ieuprorelin, levamisole, lisuride, lobaplatin, iomustine, lonidamine, masoprolol, medroxyprogesterone, megestrol, melphalan, mepitiostane, mercaptopurine, methotrexate, methoxsalen, Methyl aminolevulinate, methyltestosterone, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, nedaplatin, nelarabine, nilotinib, nilutamide, nimotuzumab, nimustine, nitracrine, ofatumumab, omeprazole, oprelvekin, oxaliplatin, p53 gene therapy, paclitaxel, palifermin, palladium-103 seed, pamidronic acid, panitumumab, pazopanib, pegaspargase, PEG-eopotin beta (methoxy PEG-eopotin beta), pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentazocine, pentostatin, peplomycin, perfosfamide, picibanil, pirarubicin, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polysaccharide-K, porfimer sodium, predni-mustine, procarbazine, quinagolide, radium-223 chloride, raltitrexed, ranimustine, razoxane, refametinib, regorafenib, risedronic acid, rituximab, ro-midepsin, romiplostim, sargramostim, sipuleucel-T, sizofiran, sobuzoxane, sodium glyciddidazole, sorafenib, streptozocin, sunitinib, talaporfin, tamibarotene, tamoxifen, tasonermin, teceleukin, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, tioguainine, tocolizumab, topotecan, toremifene, tositumomab, trabectedin, trastuzumab, treosulfan, tretinoin, trilostane, triptorelin, trofosfamide, tryptophan, ubenimex, valrubcin, vandetanib, vatreotide, vemurafenib, vinblas-tine, vincristine, vindesine, vinflunine, vinorelbine, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimulamer, zoledronic acid, zorubicin.

The compounds according to the invention and their salts can exist in the form of tautomers which are included in the embodiments of the invention.

The compounds of the Invention may, depending on their structure, exist in different stereoisomeric forms. These forms include configurational isomers or optionally conformational isomers (enantiomers and/or diastereoisomers including those of atropisomers). The present invention therefore includes enantiomers, diastereoisomers as well as mixtures thereof. From those mixtures of enantiomers and/or diastereoisomers pure stereoisomeric forms can be isolated with methods
known in the art, preferably methods of chromatography, especially high pressure liquid chromatography (HPLC) using achiral or chiral phase. The invention further includes all mixtures of the stereoisomers mentioned above independent of the ratio, including the racemates.

Some of the compounds and salts according to the invention may exist in different crystalline forms (polymorphs) which are within the scope of the invention.

Furthermore, derivatives of the compounds of formula (I) and the salts thereof which are converted into a compound of formula (I) or a salt thereof in a biological system (bioprecursors or pro-drugs) are covered by the invention. Said biological system is e.g. a mammalian organism, particularly a human subject. The bioprecursor is, for example, converted into the compound of formula (I) or a salt thereof by metabolic processes.

The intermediates used for the synthesis of the compounds of claims 1-5 as described below, as well as their use for the synthesis of the compounds of claims 1-5, are one further aspect of the present invention. Preferred intermediates are the Intermediate Examples as disclosed below.
The compounds according to the invention can be prepared as follows.
The compounds according to the invention can be prepared according to the following scheme 1,

Scheme 1:
wherein $X$, $Y$, $R^1$, $R^2$, $R^3$, $R^4$, $R^5$ and $R^6$ have the meanings defined above and in the claims, whereby $R^x$ has the meaning of $R^6$ and may also be a protecting group; $R^y$ is $H$, or a protecting group, whereby $R^y$ and $R^x$ together, or $Y$ and $R^x$ together, may form a cyclic protecting group; $Q$ is halogen, preferably CI, Br, or I. or sulfonate, preferably trifluoromethane sulfonate, nonafluorobutane sulfonate or tosylate; $R^z$ is hydrogen or lower alkyl, or both of $R^z$ together with the oxygens and boron form a 5-membered or 6-membered ring (cyclic boronic ester).

Compounds of general formula (I) may be prepared from compounds of general formula (II). $R^y$ may optionally be $R^6$, or a protecting group, or other such precursor which requires further manipulation. For example, $R^x$ in compounds of general formula (II) may be a protecting group such as the Boc group, -CO(OtBu). Thus in special embodiment of the invention the protecting group is a Boc group. Preparation of compounds of general formula (I) may thus be accomplished by use of an appropriate deprotection reaction, such as in the case of a Boc group, acidic reaction conditions, for example, with a solution of 4M hydrogen chloride in dioxane, in an appropriate solvent, such as for example DCM and methanol, at ambient temperature. The resulting ammonium salts are usually converted to the free amines by using, e.g., bases known to the skilled person, e.g., bicarbonate, amine bases such as Hunig's base (diisopropylethylamine), sodium hydroxide, ammonia, or by eluting the compounds with methanol/ammonia from a PoraPak™ column. Further conditions to deprotect the Boc group, or further protecting groups that may be suitable for use in blocking the amino functionality in compounds of general formula (II), including their synthesis and deprotection, are found, for example, in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, 1999, 3rd Ed., or in P. Kocienski, Protecting Groups, Thieme Medical Publishers, 2000. Similarly, when $R^y$ is not $H$, then $R^y$ is a protecting group, such as for example when $R^x$ and $R^y$ together form a cyclic protecting group such as for example a phthalamide.

Furthermore, compounds of general formula (II) may contain functionality that may itself be further modified, thus allowing introduction of the desired functionality in the $R^1$ or $R^2$ or $R^3$ groups. Such transformations include oxidations, reductions,
nucleophilic substitutions, electrophilic substitutions, radical reactions, or metal promoted reactions such as metal assisted cross-coupling reactions, such as for example Suzuki, Stille, or Heck reactions, or the like. Similarly, compounds of general formula (I) may also be modified in this way to provide further compounds according to the invention, providing the transformations do not cause unwanted side reactions at the -NHR group.

Compounds of general formula (II) may be prepared from an intermediate pyrazolo pyrimidine of general formula (III) and an aryl boronic acid or aryl boronic ester of general formula (IV), by use of an appropriate transition metal catalyzed coupling reaction. For example, compounds of general formula (II) may be prepared by reacting (III) and (IV) in an appropriate solvent, such as for example DMF, ethanol or isopropanol, using a suitable catalyst such as tetrakis(triphenylphosphine)-palladium(0)[Pd(PPh3)4], optionally in the presence of water and/or 1,2 dimethoxyethane at elevated temperatures from 50 °C to 150 °C. The use of basic additives such as a tertiary amine, for example triethylamine or diisopropylamine may be beneficial.

Compounds of general formula (IV) are either commercially available, may be prepared using the methods described in the examples, may be prepared using known methods, or may be prepared by analogous methods to those known by the person skilled in the art.

Compounds of general formula (III) may be prepared from a ketone of general formula (V) by use of an appropriate halogenation reaction or by reaction with an appropriate perfluoroalkylsulfonylhalide or anhydride. For example in the case of halogen is Br or Cl, a suitable halogenation reaction, such as for example by reacting a compound of general formula (V) with phosphorus(V) oxybromide or phosphorus(V) oxychloride in a suitable solvent, such as dichloromethane or 1,2-dichloroethane, at suitable temperatures, such as for example from 0 °C to reflux temperature, optionally in the presence of catalytic amounts of suitable amines, such as 4-dimethylaminopyridine or N,N-diethylaniline.
Compounds of general formula (V) may be prepared from a compound of general formula (VI), which is either commercially available or can be prepared by methods known in the art, by reaction with 2-cyano-2-phenylacetohydrazide. The latter compound is available via treatment of the corresponding ethyl ester with hydrazine-hydrate as published recently [Drummond, J. T., Johnson, G., J. Heterocycl. Chem (1988), 25, 1123-1127], by heating in acetic acid at elevated temperatures.

Thus one aspect of the invention is the process for the manufacture of compounds of general formula (I), characterized in that a compound of formula (III)

\[
\begin{align*}
\text{III} & \\
R^1 & \\
R^2 & \\
R^3 & \\
N & \\
N & \\
Q \\
\end{align*}
\]

whereby \( R^1, R^2 \) and \( R^3 \), have the meaning according to claim 1 and \( Q \) is halogen, preferably Cl, Br, or I, or sulfonate, preferably trifluoromethane sulfonate, nonafluorobutane sulfonate ortosylate,

is reacted with a compound of formula (IV)

\[
\begin{align*}
\text{IV} & \\
R^5 & \\
Y & \\
X & \\
R^x & \\
R^y & \\
\end{align*}
\]

whereby \( R^5, Y, X, R^x \) and \( R^y \) have the meaning according to claim 1 and \( R^z \) is hydrogen or lower alkyl, or both of \( R^z \) together with the oxygens and boron form a 5-membered or 6-membered ring,

forming a compound of formula (II)
Another aspect of the invention is the intermediate compound of general formula II

\[
\begin{align*}
&\text{wherein } R^1, R^2, R^3, R^5, R^6, X \text{ and } Y \text{ have the meaning as defined in claim 1 and } R^x \\
&\text{is } R^8 \text{ or a protecting group; } R^y \text{ is hydrogen or a protecting group, or } R^x \text{ and } R^y \text{ to-}
\end{align*}
\]

gether, or } Y \text{ and } R^x \text{ together, may form a cyclic protecting group as well as its use}

For the processes described above it is preferred that } R^x \text{ is } R^8 \text{ or a protecting group and } R^y \text{ is hydrogen or a protecting group. In one embodiment of the}

invention one of } R^y/Ry \text{ is a protecting group and the other is hydrogen. Especially}

preferred protecting groups are the ones disclosed in the experimental section.

It is known to the person skilled in the art that, if there are a number of reactive centers on a starting or intermediate compound, it may be necessary to block one or more reactive centers temporarily by protective groups in order to allow a reaction to proceed specifically at the desired reaction center. A detailed
description for the use of a large number of proven protective groups is found, for example, in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, 1999, 3rd Ed., or in P. Kocienski, Protecting Groups, Thieme Medical Publishers, 2000.

The compounds according to the invention are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as chromatography on a suitable support material. Furthermore, reverse phase preparative HPLC of compounds of the present invention which possess a sufficiently basic or acidic functionality, may result in the formation of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. Salts of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. Additionally, the drying process during the isolation of compounds of the present invention may not fully remove traces of cosolvents, especially such as formic acid or trifluoroacetic acid, to give solvates or inclusion complexes. The person skilled in the art will recognise which solvates or inclusion complexes are acceptable to be used in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base, solvate, inclusion complex) of a compound of the present invention as isolated as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.

Salts of the compounds of formula (I) according to the invention can be obtained by dissolving the free compound in a suitable solvent (for example a ketone such as acetone, methylethylketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to
which the desired acid or base is then added. The acid or base can be employed in salt preparation, depending on whether a mono- or polybasic acid or base is concerned and depending on which salt is desired, in an equimolar quantitative ratio or one differing therefrom. The salts are obtained by filtering, reprecipitating, precipitating with a non-solvent for the salt or by evaporating the solvent. Salts obtained can be converted into the free compounds which, in turn, can be converted into salts. In this manner, pharmaceutically unacceptable salts, which can be obtained, for example, as process products in the manufacturing on an industrial scale, can be converted into pharmaceutically acceptable salts by processes known to the person skilled in the art.

Pure diastereomers and pure enantiomers of the compounds and salts according to the invention can be obtained e.g. by asymmetric synthesis, by using chiral starting compounds in synthesis and by splitting up enantiomeric and diastereomeric mixtures obtained in synthesis.

Enantiomeric and diastereomeric mixtures can be split up into the pure enantiomers and pure diastereomers by methods known to a person skilled in the art. Preferably, diastereomeric mixtures are separated by crystallization, in particular fractional crystallization, or chromatography. Enantiomeric mixtures can be separated e.g. by forming diastereomers with a chiral auxiliary agent, resolving the diastereomers obtained and removing the chiral auxiliary agent. As chiral auxiliary agents, for example, chiral acids can be used to separate enantiomeric bases such as e.g. mandelic acid and chiral bases can be used to separate enantiomeric acids via formation of diastereomeric salts. Furthermore, diastereomeric derivatives such as diastereomeric esters can be formed from enantiomeric mixtures of alcohols or enantiomeric mixtures of acids, respectively, using chiral acids or chiral alcohols, respectively, as chiral auxiliary agents. Additionally, diastereomeric complexes or diastereomeric clathrates may be used for separating enantiomeric mixtures. Alternatively, enantiomeric mixtures can be split up using chiral separating columns in chromatography. Another suitable method for the isolation of enantiomers is the enzymatic separation.
One preferred aspect of the invention is the process for the preparation of the compounds of claims 1-5 according to the examples.

Optionally, compounds of the formula (I) can be converted into their salts, or, optionally, salts of the compounds of the formula (I) can be converted into the free compounds. Corresponding processes are customary for the skilled person.

Optionally, compounds of the formula (I) can be converted into their N-oxides. The N-oxide may also be introduced by way of an intermediate. N-oxides may be prepared by treating an appropriate precursor with an oxidizing agent, such as meta-chloroperbenzoic acid, in an appropriate solvent, such as dichloromethane, at suitable temperatures, such as from 0 °C to 40 °C, whereby room temperature is generally preferred. Further corresponding processes for forming N-oxides are customary for the skilled person.

Commercial utility

The compounds of formula (I) and the stereoisomers of the compounds of formula (I) according to the invention are hereinafter referred to as the compounds of the invention. In particular, the compounds of the invention are pharmaceutically acceptable. The compounds according to the invention have valuable pharmaceutical properties, which make them commercially utilizable. In particular, they inhibit the PI3K/Akt pathway and exhibit cellular activity. They are expected to be commercially applicable in the therapy of diseases (e.g. diseases dependent on overactivated PI3K/Akt). An abnormal activation of the PI3K/AKT pathway is an essential step towards the initiation and maintenance of human tumors and thus its inhibition, for example with AKT inhibitors, is understood to be a valid approach for treatment of human tumors. For a recent review see Garcia-Echeverria et al (Oncogene, 2008, 27, 551-5526).

Cellular activity and analogous terms in the present invention is used as known to persons skilled in the art, as an example, inhibition of phosphorylation, inhibition of cellular proliferation, induction of apoptosis or chemosensitization.
Chemosensitization and analogous terms in the present invention is used as known to persons skilled in the art. These stimuli include, for example, effectors of death receptor and survival pathways as well as cytotoxic / chemotherapeutic and targeted agents and finally radiation therapy. Induction of apoptosis and analogous terms according to the present invention are used to identify a compound which executes programmed cell death in cells contacted with that compound or in combination with other compounds routinely used for therapy.

Apoptosis in the present invention is used as known to persons skilled in the art. Induction of apoptosis in cells contacted with the compound of this invention might not necessarily be coupled with inhibition of cell proliferation. Preferably, the inhibition of proliferation and/or induction of apoptosis are specific to cells with aberrant cell growth.

Furthermore, the compounds according to the present invention inhibit protein kinase activity in cells and tissues, causing a shift towards dephosphorylated substrate proteins and as functional consequence, for example the induction of apoptosis, cell cycle arrest and/or sensitization towards chemotherapeutic and target-specific cancer drugs. In a preferred embodiment, inhibition of the PI3K/Akt pathway induces cellular effects as mentioned herein, alone, or in combination with standard cytotoxic or targeted cancer drugs.

In addition, inhibition of AKT signaling pathway was found to inhibit retinal neovascularisation in the oxygen induced retinopathy model as well as a potential therapeutic use of a AKT inhibition on choroidal neovascularisation was shown (Wang et al., Acta Histochem. Cytochem. 44(2): 103-11, 2011; Yang et al., Investigative Ophthalmology & Visual Science (IOVS), April 2009, Vol. 50, No. 4) These results lead to the conclusion that AKT inhibition could provide a useful therapy for ocular diseases associated with ocular neovascularisation like e.g. AMD, MD und diabetic retinopathy.

Thus one embodiment of the invention includes methods of treatment of ocular diseases associated with ocular neovasculariation especially AMD, MD und dia-
betic retinopathy comprising administering a compound of general formula (I) as well as the use of those compounds for the treatment of said diseases.

Compounds according to the present invention exhibit anti-proliferative and/or pro-apoptotic and/or chemosensitizing properties. Accordingly, the compounds of the present invention are useful for the treatment of hyperproliferative disorders, in particular cancer. Therefore the compounds of the present invention are useful to induce an anti-proliferative and/or pro-apoptotic and/or chemosensitizing effect in mammals, such as humans, suffering from a hyperproliferative disorders, like cancer.

The invention further relates to a compound according to the invention or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis, preferably treatment of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis, which include benign neoplasia and malignant neoplasia, especially malignant neoplasia, including cancer and the tumor types as disclosed below.

Compounds according to the present invention exhibit anti-proliferative and/or pro-apoptotic properties in mammals such as humans due to inhibition of metabolic activity of cancer cells which are able to survive despite of unfavourable growth conditions such as glucose depletion, hypoxia or other chemo stress.

Thus, the compounds according to the present invention are useful for treating, ameliorating or preventing diseases of benign or malignant behaviour as described herein, such as e.g. for inhibiting cellular neoplasia.

Neoplasia in the present invention is used as known to persons skilled in the art. A benign neoplasia is described by hyperproliferation of cells, incapable of forming an aggressive, metastasizing tumor in-vivo. In contrast, a malignant neoplasia is described by cells with multiple cellular and biochemical abnormalities, capable of forming a systemic disease, for example forming tumor metastasis in distant organs.
The compounds according to the present invention can be preferably used for the treatment of malignant neoplasia. Examples of malignant neoplasia treatable with the compounds according to the present invention include solid and hematological tumors. Solid tumors can be exemplified by tumors of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands (e.g. thyroid and adrenal cortex), esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva. Malignant neoplasias include inherited cancers exemplified by Retinoblastoma and Wilms tumor. In addition, malignant neoplasias include primary tumors in said organs and corresponding secondary tumors in distant organs ("tumor metastases"). Hematological tumors can be exemplified by aggressive and indolent forms of leukemia and lymphoma, namely non-Hodgkin's disease, chronic and acute myeloid leukemia (CML / AML), acute lymphoblastic leukemia (ALL), Hodgkin's disease, multiple myeloma and T-cell lymphoma. Also included are myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, and cancers of unknown primary site as well as AIDS related malignancies.

The invention further includes as a preferred embodiment methods for treatment of melanoma, NSCLC, brain-breast- and prostate cancer, more preferred breast cancer, comprising administering a compound of general formula (I) as well as the use of the compounds of general formula (I) for said treatment. Another aspect of the invention is the use of the compounds of the invention for the treatment of melanoma as well as methods for treatment of melanoma for which the data in view of the publication of O'Reilly et al. (Clin.Cancer Research, 15, 2009, 2872) give a basis.

It is noted that a malignant neoplasia does not necessarily require the formation of metastases in distant organs. Certain tumors exert devastating effects on the primary organ itself through their aggressive growth properties. These can lead to the destruction of the tissue and organ structure finally resulting in failure of the assigned organ function and death.
Drug resistance is of particular importance for the frequent failure of standard cancer therapeutics. This drug resistance is caused by various cellular and molecular mechanisms. One aspect of drug resistance is caused by constitutive activation of anti-apoptotic survival signals with PKB/Akt as a key signalling kinase. Inhibition of the PI3K/Akt pathway leads to a resensitization towards standard chemotherapeutic or target specific cancer therapeutics. As a consequence, the commercial applicability of the compounds according to the present invention is not limited to 1st line treatment of cancer patients. In a preferred embodiment, cancer patients with resistance to cancer chemotherapeutics or target specific anti-cancer drugs are also amenable for treatment with these compounds for e.g. 2nd or 3rd line treatment cycles. In particular, the compounds according to the present invention might be used in combination with standard chemotherapeutic or targeted drugs to resensitize tumors towards these agents.

Compounds according to the present invention are suitable for treatment, prevention or amelioration of the diseases of benign and malignant behavior as described above, such as e.g. benign or malignant neoplasia, particularly cancer, especially a cancer that is sensitive to PI3K/Akt pathway inhibition.

The present invention further includes a method for treating, preventing or ameliorating mammals, including humans, preferably treating mammals, including humans, which are suffering from one of the abovementioned conditions, illnesses, disorders or diseases. The method is characterized in that a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention is administered to the subject in need of such treatment.

The present invention further includes a method for treating, preventing or ameliorating diseases responsive to inhibition of the PI3K/Akt pathway, in a mammal, including human, preferably treating diseases responsive to inhibition of the PI3K/Akt pathway, in a mammal, including human, comprising administering a
pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to said mammal.

The present invention further includes a method for inhibiting protein kinase activity in cells comprising administering a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to a patient in need of such therapy.

The present invention further includes a method for inhibiting cellular hyperproliferation or arresting aberrant cell growth in a mammal, comprising administering a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to said mammal.

The present invention further includes a method for inducing apoptosis in the therapy of benign or malignant neoplasia, particularly cancer, comprising administering a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to a subject in need of such therapy.

The present invention further includes a method for inhibiting protein kinase activity in cells comprising administering a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to a patient in need of such therapy.

The present invention further includes a method for sensitizing towards chemotherapeutic or target-specific anti-cancer agents in a mammal, comprising adminis-
tering a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to said mammal.

The present invention further includes a method for treating benign and/or malignant neoplasia, especially malignant neoplasia, particularly cancer, in a mammal, including human, comprising administering a pharmacologically active and therapeutically effective and tolerable amount of one or more of the compounds according to the present invention to said mammal.

The present invention further includes a method for treating solid and hematological tumors, whereby solid tumors can be exemplified by tumors of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands (e.g. thyroid and adrenal cortex), esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva. Malignant neoplasias include inherited cancers exemplified by Retinoblastoma and Wilms tumor. In addition, malignant neoplasias include primary tumors in said organs and corresponding secondary tumors in distant organs ("tumor metastases"). and hematological tumors can be exemplified by aggressive and indolent forms of leukemia and lymphoma, namely non-Hodgkins disease, chronic and acute myeloid leukemia (CML / AML), acute lymphoblastic leukemia (ALL), Hodgkins disease, multiple myeloma and T-cell lymphoma. Also included are myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, and cancers of unknown primary site as well as AIDS related malignancies.

The present invention further relates to the use of the compounds for the production of pharmaceutical compositions, which are employed for the treatment, prophylaxis, and/or amelioration of one or more of the illnesses mentioned, preferably for the treatment of one or more of the illnesses mentioned.
The present invention further relates to the use of the compounds for the manufacture of pharmaceutical compositions for treating, preventing or ameliorating, preferably treating hyperproliferative diseases and/or disorders responsive to the induction of apoptosis, such as e.g. benign or malignant neoplasia, especially malignant neoplasia, in particular cancer, especially those cancer diseases and tumor types mentioned above.

The present invention further relates to the use of the compounds according to this invention for the production of pharmaceutical compositions for treating, preventing or ameliorating, preferably treating benign or malignant neoplasia, especially malignant neoplasia, particularly cancer, such as e.g. any of those cancer diseases and tumor types described above.

The invention further relates to a compound according to the invention or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis, preferably treatment of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis, which include benign neoplasia and malignant neoplasia, including cancer.

The invention further relates to the use of a compound according to the invention or a pharmaceutically acceptable salt thereof, for the production of a pharmaceutical composition for the treatment, prevention or amelioration of a disease mediated by a dysregulated function of a single protein kinase or multiple protein kinases and/or disorders responsive to the induction of apoptosis.

The invention further relates to a pharmaceutical composition, comprising a compound according to the invention or a pharmaceutically acceptable salt thereof, for the treatment and/or prophylaxis, preferably treatment of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis, which include benign neoplasia and malignant neoplasia, including cancer.

The present invention further relates to the use of compounds and pharmaceutically acceptable salts according to the present invention for the manufacture of
pharmaceutical compositions, which can be used for sensitizing towards chemotherapeutic and/or target specific anti-cancer agents.

The present invention further relates to the use of compounds according to the present invention for the manufacture of pharmaceutical compositions, which can be used for sensitizing towards radiation therapy of those diseases mentioned herein, particularly cancer.

The present invention further relates to the use of the compounds according to the present invention for the manufacture of pharmaceutical compositions, which can be used in the treatment of diseases sensitive to protein kinase inhibitor therapy and different to cellular neoplasia. These non-malignant diseases include, but are not limited to benign prostate hyperplasia, neurofibromatosis, dermatoses, and myelodysplastic syndromes.

The present invention further relates to pharmaceutical compositions comprising one or more of the compounds according to this invention and a pharmaceutically acceptable carrier or diluent.

The present invention further relates to pharmaceutical compositions comprising one or more of the compounds according to this invention and pharmaceutically acceptable auxiliaries and/or excipients.

The pharmaceutical compositions according to this invention are prepared by processes, which are known per se and familiar to the person skilled in the art. As pharmaceutical compositions, the compounds of the invention (= active compounds) are either employed as such, or preferably in combination with suitable pharmaceutical auxiliaries and/or excipients, e.g. in the form of tablets, coated tablets, dragees, pills, cachets, granules, capsules, caplets, suppositories, patches (e.g. as TTS), emulsions (such as e.g. micro-emulsions or lipid emulsions), suspensions (such as e.g. nano suspensions), gels, solubilisates or solutions (e.g. sterile solutions), or encapsulated in liposomes or as beta-cyclodextrin or beta-cyclodextrin derivative inclusion complexes or the like, the active compound con-
tent advantageously being between 0.1 and 95% and where, by the appropriate choice of the auxiliaries and/or excipients, a pharmaceutical administration form (e.g. a delayed release form or an enteric form) exactly suited to the active compound and/or to the desired onset of action can be achieved.

The person skilled in the art is familiar with auxiliaries, vehicles, excipients, diluents, carriers or adjuvants which are suitable for the desired pharmaceutical formulations, preparations or compositions on account of his/her expert knowledge. In addition to solvents, gel formers, ointment bases and other active compound excipients, for example antioxidants, dispersants, emulsifiers, preservatives, solubilizers (such as e.g. polyoxyethylene glyc eroltriricinoleat 35, PEG 400, Tween 80, Captisol, Solutol HS15 or the like), colorants, complexing agents, permeation promoters, stabilizers, fillers, binders, thickeners, disintegrating agents, buffers, pH regulators (e.g. to obtain neutral, alkaline or acidic formulations), polymers, lubricants, coating agents, propellents, tonicity adjusting agents, surfactants, flavorings, sweeteners or dyes, can be used.

In particular, auxiliaries and/or excipients of a type appropriate to the desired formulation and the desired mode of administration are used.

The administration of the compounds, pharmaceutical compositions or combinations according to the invention may be performed in any of the generally accepted modes of administration available in the art. Illustrative examples of suitable modes of administration include intravenous, oral, nasal, parenteral, topical, transdermal and rectal delivery. Oral and intravenous deliveries are preferred.

Generally, the pharmaceutical compositions according to the invention can be administered such that the dose of the active compound is in the range customary for PI3K/Akt pathway inhibitors. In particular, a dose in the range of from 0.01 to 4000 mg of the active compound per day is preferred for an average adult patient having a body weight of 70 kg. In this respect, it is to be noted that the dose is dependent, for example, on the specific compound used, the species treated, age, body weight, general health, sex and diet of the subject treated, mode and time of
administration, rate of excretion, severity of the disease to be treated and drug combination.

The pharmaceutical composition can be administered in a single dose per day or in multiple subdoses, for example, 2 to 4 doses per day. A single dose unit of the pharmaceutical composition can contain e.g. from 0.01 mg to 4000 mg, preferably 0.1 mg to 2000 mg, more preferably 0.5 to 1500 mg, most preferably 1 to 500 mg, of the active compound. Furthermore, the pharmaceutical composition can be adapted to weekly, monthly or even more infrequent administration, for example by using an implant, e.g. a subcutaneous or intramuscular implant, by using the active compound in form of a sparingly soluble salt or by using the active compound coupled to a polymer.

The present invention further relates to combinations comprising one or more first active ingredients selected from the compounds of the invention and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents e.g. for treating, preventing or ameliorating diseases responsive or sensitive to inhibition of the PI3K/Akt pathway, such as hyperproliferative diseases of benign or malignant behaviour and/or disorders responsive to the induction of apoptosis, particularly cancer, such as e.g. any of those cancer diseases described above.

The invention further relates to the use of a pharmaceutical composition comprising one or more of the compounds according to this invention as sole active ingredient(s) and a pharmaceutically acceptable carrier or diluent in the manufacture of pharmaceutical products for the treatment and/or prophylaxis of the illnesses mentioned above.

Depending upon the particular disease, to be treated or prevented, additional therapeutic active agents, which are normally administered to treat or prevent that disease, may optionally be coadministered with the compounds according to this invention. As used herein, additional therapeutic agents that are normally adminis-
tered to treat or prevent a particular disease are known as appropriate for the disease being treated.

The anti-cancer agents mentioned herein above as combination partners of the compounds according to this invention are meant to include pharmaceutically acceptable derivatives thereof, such as e.g. their pharmaceutically acceptable salts.

The person skilled in the art is aware of the total daily dosage(s) and administration form(s) of the additional therapeutic agent(s) coadministered. Said total daily dosage(s) can vary within a wide range depending from the agent combined.

In practicing the present invention, the compounds according to this invention may be administered in combination therapy separately, sequentially, simultaneously, concurrently or chronologically staggered (such as e.g. as combined unit dosage forms, as separate unit dosage forms, as adjacent discrete unit dosage forms, as fixed or non-fixed combinations, as kit-of-parts or as admixtures) with one or more standard therapeutics (chemotherapeutic and/or target specific anti-cancer agents), in particular art-known anti-cancer agents, such as any of e.g. those mentioned above.

In this context, the present invention further relates to a combination comprising a first active ingredient, which is at least one compound according to this invention, and a second active ingredient, which is at least one art-known anti-cancer agent, such as e.g. one or more of those mentioned herein above, for separate, sequential, simultaneous, concurrent or chronologically staggered use in therapy, such as e.g. in therapy of any of those diseases mentioned herein.

The present invention further relates to a pharmaceutical composition comprising a first active ingredient, which is at least one compound according to this invention, and a second active ingredient, which is at least one art-known anti-cancer agent, such as e.g. one or more of those mentioned herein above, and, optionally, a pharmaceutically acceptable carrier or diluent, for separate, sequential, simultaneous, concurrent or chronologically staggered use in therapy.
The present invention further relates to a combination product comprising
a.) at least one compound according to this invention formulated with a pharma-
ceutically acceptable carrier or diluent, and
b.) at least one art-known anti-cancer agent, such as e.g. one or more of those
mentioned herein above, formulated with a pharmaceutically acceptable carrier or
diluent.

The present invention further relates to a kit-of-parts comprising a preparation of a
first active ingredient, which is a compound according to this invention, and a
pharmaceutically acceptable carrier or diluent; a preparation of a second active
ingredient, which is an art-known anti-cancer agent, such as one of those men-
tioned above, and a pharmaceutically acceptable carrier or diluent; for simul-
taneous, concurrent, sequential, separate or chronologically staggered use in
therapy. Optionally, said kit comprises instructions for its use in therapy, e.g. to
treat hyperproliferative diseases and diseases responsive or sensitive to inhibition
of the Pi3K/Akt pathway, such as e.g. benign or malignant neoplasia, particularly
cancer, more precisely, any of those cancer diseases described above.

The present invention further relates to a combined preparation comprising at least
one compound according to this invention and at least one art-known anti-cancer
agent for simultaneous, concurrent, sequential or separate administration.

The present invention further relates to combinations, compositions, formulations,
preparations or kits according to the present invention having Pi3K/Akt pathway
inhibitory activity.

In addition, the present invention further relates to a method for treating in combi-
nation therapy hyperproliferative diseases and/or disorders responsive to the in-
duction of apoptosis, such as e.g. cancer, in a patient comprising administering a
combination, composition, formulation, preparation or kit as described herein to
said patient in need thereof.
In addition, the present invention further relates to a method for treating hyperproliferative diseases of benign or malignant behaviour and/or disorders responsive to the induction of apoptosis, such as e.g. cancer, in a patient comprising administering in combination therapy separately, simultaneously, concurrently, sequentially or chronologically staggered a pharmacologically active and therapeutically effective and tolerable amount of a pharmaceutical composition, which comprises a compound according to this invention and a pharmaceutically acceptable carrier or diluent, and a pharmaceutically active and therapeutically effective and tolerable amount of one or more art-known anti-cancer agents, such as e.g. one or more of those mentioned herein, to said patient in need thereof.

In further addition, the present invention relates to a method for treating, preventing or ameliorating hyperproliferative diseases and/or disorders responsive to induction of apoptosis, such as e.g. benign or malignant neoplasia, e.g. cancer, particularly any of those cancer diseases mentioned herein, in a patient comprising administering separately, simultaneously, concurrently, sequentially or chronologically staggered to said patient in need thereof an amount of a first active compound, which is a compound according to the present Invention, and an amount of at least one second active compound, said at least one second active compound being a standard therapeutic agent, particularly at least one art-known anti-cancer agent, such as e.g. one or more of those chemotherapeutic and target-specific anti-cancer agents mentioned herein, wherein the amounts of the first active compound and said second active compound result in a therapeutic effect.

In yet further addition, the present invention relates to a method for treating, preventing or ameliorating, especially treating hyperproliferative diseases and/or disorders responsive to induction of apoptosis, such as e.g. benign or malignant neoplasia, especially malignant neoplasia, e.g. cancer, particularly any of those cancer diseases and tumor types mentioned herein, in a patient comprising administering a combination according to the present invention.

In addition, the present invention further relates to the use of a composition, combination, formulation, preparation or kit according to this invention in the manufac-
ture of a pharmaceutical product, such as e.g. a commercial package or a medicament, for treating, preventing or ameliorating, especially treating hyperproliferative diseases, and/or disorders responsive to the induction of apoptosis, such as e.g. malignant or benign neoplasia, especially malignant neoplasia, such as e.g. cancer, particularly those diseases and tumor types mentioned herein.

The present invention further relates to a commercial package comprising one or more compounds of the present invention together with instructions for simultaneous, concurrent, sequential or separate use with one or more chemotherapeutic and/or target specific anti-cancer agents, such as e.g. any of those mentioned herein.

The present invention further relates to a commercial package consisting essentially of one or more compounds of the present invention as sole active ingredient together with instructions for simultaneous, concurrent, sequential or separate use with one or more chemotherapeutic and/or target specific anti-cancer agents, such as e.g. any of those mentioned herein.

The present invention further relates to a commercial package comprising one or more chemotherapeutic and/or target specific anti-cancer agents, such as e.g. any of those mentioned herein, together with instructions for simultaneous, concurrent, sequential or separate use with one or more compounds according to the present invention.

The compositions, combinations, preparations, formulations, kits or packages mentioned in the context of the combination therapy according to this invention may also include more than one of the compounds according to this invention and/or more than one of the art-known anti-cancer agents mentioned.

The first and second active ingredient of a combination or kit-of-parts according to this invention may be provided as separate formulations (i.e. independently of one another), which are subsequently brought together for simultaneous, concurrent, sequential, separate or chronologically staggered use in combination therapy; or
packaged and presented together as separate components of a combination pack for simultaneous, concurrent, sequential, separate or chronologically staggered use in combination therapy.

The type of pharmaceutical formulation of the first and second active ingredient of a combination or kit-of-parts according to this invention can be according, i.e. both ingredients are formulated in separate tablets or capsules, or can be different, i.e. suited for different administration forms, such as e.g. one active ingredient is formulated as tablet or capsule and the other is formulated for e.g. intravenous administration.

The amounts of the first and second active ingredients of the combinations, compositions or kits according to this invention may together comprise a therapeutically effective amount for the treatment, prophylaxis or amelioration of a hyperproliferative diseases and/or a disorder responsive to the induction of apoptosis, particularly one of those diseases mentioned herein, such as e.g. malignant or benign neoplasia, especially malignant neoplasia, e.g. cancer, like any of those cancer diseases and tumor types mentioned herein.

In addition, compounds according to the present invention can be used in the pre- or post-surgical treatment of cancer.

In further addition, compounds of the present invention can be used in combination with radiation therapy.

As will be appreciated by persons skilled in the art, the invention is not limited to the particular embodiments described herein, but covers all modifications of said embodiments that are within the spirit and scope of the invention as defined by the appended claims.

The following examples illustrate the invention in greater detail, without restricting it. Further compounds according to the invention, of which the preparation is not explicitly described, can be prepared in an analogous way.
The compounds, which are mentioned in the examples and the salts thereof represent preferred embodiments of the invention as well as a claim covering all subcombinations of the residues of the compound of formula (I) as disclosed by the specific examples.

The term "according to" within the experimental section is used in the sense that the procedure referred to is to be used "analogously to".
**Experimental** part

The following table lists the abbreviations used in this paragraph and in the Intermediate Examples and Examples section as far as they are not explained within the text body. A comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears presented in the first issue of each volume of the *Journal of Organic Chemistry*, this list is typically presented in a table entitled Standard List of Abbreviations. The abbreviations contained therein, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference. NMR peak forms are stated as they appear in the spectra, possible higher order effects have not been considered.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>boc</td>
<td><em>tert</em>-Butoxycarbonyl</td>
</tr>
<tr>
<td>br</td>
<td>broad</td>
</tr>
<tr>
<td>Cl</td>
<td>chemical ionisation</td>
</tr>
<tr>
<td>d</td>
<td>doublet</td>
</tr>
<tr>
<td>dd</td>
<td>doublet of doublet</td>
</tr>
<tr>
<td>DAD</td>
<td>diode array detector</td>
</tr>
<tr>
<td>DCM</td>
<td>dichloromethane</td>
</tr>
<tr>
<td>EtOAc</td>
<td>ethyl acetate</td>
</tr>
<tr>
<td>eq</td>
<td>equivalent</td>
</tr>
<tr>
<td>ESI</td>
<td>electrospray (ES) ionisation</td>
</tr>
<tr>
<td>HPLC</td>
<td>high performance liquid chromatography</td>
</tr>
<tr>
<td>LC-MS</td>
<td>liquid chromatography mass spectrometry</td>
</tr>
<tr>
<td>m</td>
<td>multiplet</td>
</tr>
<tr>
<td>MS</td>
<td>mass spectrometry</td>
</tr>
<tr>
<td>NMR</td>
<td>nuclear magnetic resonance spectroscopy</td>
</tr>
<tr>
<td>q</td>
<td>quartet</td>
</tr>
<tr>
<td>r.t. or t</td>
<td>room temperature</td>
</tr>
<tr>
<td>RT</td>
<td>retention time</td>
</tr>
<tr>
<td>s</td>
<td>singlet</td>
</tr>
<tr>
<td>t</td>
<td>triplet</td>
</tr>
</tbody>
</table>
Other abbreviations have their meanings customary per se to the skilled person. The various aspects of the invention described in this application are illustrated by the following examples which are not meant to limit the invention in any way.

Examples

**UPLC-MS Standard Procedures**

Analytical UPLC-MS was performed using UPLC-MS Method 1 unless otherwise stated. The masses (m/z) are reported from the positive mode electrospray ionisation unless the negative mode is indicated (ES-). Purity is reported as the % area of the product peak compared to the total area as measured by the UV detector, unless otherwise stated.

**UPLC-MS Method 1**

Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.1% formic acid, eluent B: acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 µL; DAD scan: 210-400 nm; ELSD

**UPLC-MS Method 2**

Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.2% ammonia, Eluent B: acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 µL; DAD scan: 210-400 nm; ELSD

**UPLC-MS Method 3**

Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1 mm; eluent A: water + 0.1% ammonia, eluent b: acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; injection: 2 µL; DAD scan: 210-400 nm; ELSD
UPLC-MS Method 4

instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50x2.1mm; eluent A: water + 0.2% ammonia, eluent B: acetonitrile;

gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60°C; injection: 2 µl; DAD scan: 210-400 nm; ELSD
Intermediate Examples
intermediate Example Int-1:

fert-Butyl {1-[4-(5,7-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]-cyclobutyl}carbamate

Step 1: 2-Cyano-2-phenylacetohydrazide [Int-1A]

The title compound is available via treatment of the corresponding ethyl ester with hydrazine-hydrate as published recently [Drummond, J. T., Johnson, G., J. Heterocycl. Chem (1988), 25, 1123-1127].

Step 2: 5,7-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-ol

2-cyano-2-phenylacetohydrazide [Int-1A] (3.27 g, 18.3 mmol, 1.0 eq) and pentane-2,4-dione (1.89 mL, 18.3 mmol, 1.0 eq) were dissolved in 59 mL acidic acid and stirred for 3 h at 60 °C. The resulting yellow suspension was cooled to rt and the precipitate was isolated by filtration. The solid was washed with hexane and dried to give 1.20 g (27% yield) of the title compound.

UPLC-MS (Method 3): $RT = 1.12 \text{ min}; m/z = 240$ (ES $^+$: M+H $^+$).

$^1$H-NMR (400 MHz, DMSO-d$_6$): $\delta$ [ppm] = 2.59 (d, 3H), 6.77 (d, 1H), 7.12 (m, 1H), 7.36 (t, 2H), 8.22 (m, 2H), 1.56 (s br, 1H), (3H covered by solvent signal).
Step 3: 5,7-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate

To a mixture of 5,7-dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-ol (1.20 g, 5.02 mmol, 1.0 eq) in 32 mL DCM was added triethylamine (1.05 mL, 7.52 mmol, 1.5 eq). The reaction mixture was cooled to 0 °C and trifluoromethanesulfonic anhydride (0.93 mL, 5.52 mmol, 1.1 eq) was added dropwise. The mixture was stirred for 10 min at 0°C and then for 1 h at rt. After addition of DCM and water, the organic phase was washed with brine and was filtered through a silicon filter. The crude product was dried and gave 1.96 g of the title compound in 97% purity based on UPLC-MS (area-%) which corresponds to a yield of >95%.

UPLC-MS (Method 1): RT = 1.53 min; m/z = 372 (ES+: M+H)+.

Step 4: tert-Butyl [1-(4-bromophenyl)cyclobutyl]carbamate

1-(4-Bromophenyl)cyclobutanamine hydrochloride [CAS 1193389-40-0] (8.99 g, 34.24 mmol, 1.0 eq) was dissolved in DCM and washed sequentially with aqueous sodium bicarbonate and water, and the organic portion was dried and concentrated.

The resulting material was dissolved in dry THF (120 mL) and diisopropylethylamine (17.62 mL, 102.7 mmol, 3.0 eq) under nitrogen, and a solution of dl-tert-butylidicarbonate (8.22 g, 37.6 mmol, 1.1 eq) in THF (20 mL) was added. The reaction was stirred at rt overnight. The mixture was partitioned between EtOAc and water and the extracted organic phase was washed with brine and concentrated in vacuo to give the title compound.

Alternatively, the title compound may be prepared by known methods (e.g. WO2008/70041).
Step 5: fert-Butyl {1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-cyclobutyl}carbamate [Int-1 B]

5 27.75 g (55 mmol) [1-(4-Bromophenyl)cyclobutyl]carbamic acid tert-butyl ester, 23.76 mmol (93.6 mmol) bis-(pinacolato)diboron, 25 g (255 mmol) potassium acetate and 2.08 g (2.55 mmol) 1,1'-bis(diphenylphosphino)ferrocenedichloropalladium(II) in 500 mL degassed THF were heated for three hours at reflux. The colour of the reaction mixture turned from dark red to black. Due to an incomplete reaction heating was continued for another two hours. The reaction mixture was poured on water (400 mL) and diluted with ethyl acetate (700 mL). After stirring for 30' the organic phase was separated and the aqueous phase was reextracted twice with ethyl acetate (400 and 200 mL). The combined organic extracts were washed with brine (200 mL) and dried (sodium sulfate). After evaporation of the solvent the residue was purified by chromatography (Biotage) yielding 28.99 g (91.3%) of the title compound.

1H NMR (400 MHz, DMSO-d6): δ 7.51-7.67 (m, 3H), 7.38 (d, 2H), 2.22-2.42 (m, 4H), 1.88-2.02 (m, 1H), 1.63-1.80 (m, 1H), 1.00-1.38 (m, 21H) ppm.

Step 6: 5,7-Dimethyl 1-3-phenyl pyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate
5,7-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate (490 mg, 1.25 mmol, 1 eq, see step 3) tert-butyl [1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclobutyl]carbamate [Int-1 B] (702 mg, 1.88 mmol, 1.5 eq), 1,1'-bis(diphenylphosphino)ferroene-palladium(II)dichloride dichloromethane complex (112 mg, 0.14 mmol, 0.1 eq) and cesium carbonate (1.02 g, 3.13 mmol, 2.5 eq) were dissolved in 9.7 ml DMF and heated under microwave irradiation to a temperature of 110°C. After a hold time of 40 sec the reaction mixture was cooled to rt. The reaction was repeated four times in identical manner and afterwards the reaction mixtures of the four runs were combined. The solvent was removed by the use of a rotary evaporator and the resulting crude material was purified by preparative MPLC [Biotage Isolera: SNAP cartridge KP-NH, hexane → hexane / ethyl acetate (4/1)] to give 650 mg (26 %) of the title compound.

UPLC-MS (Method 1): RT = 1.60 min; m/z = 469 (ES*: M+H)⁺.

Intermediate Example Int-2:
 tert-Butyl [1-[4-(5,7-diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]-cyclobutyl]carbamate

Step 1: 5,7-Diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-ol

2-Cyano-2-phenylacetohydrazide [Int-1 A] (8.40 g, 43.2 mmol, 1.0 eq) and heptane-3,5-dione (5.85 mL, 43.2 mmol, 1.0 eq) were dissolved in 140 mL acidic acid and stirred for 4.5 h at 60 °C. The resulting suspension was cooled to rt and the precipitate was isolated by filtration. The solid was washed with hexane and dried to give 4.17 g (29% yield) of the title compound.
UPLC-MS (Method 1): RT = 1.31 min; m/z = 268 (ES\(^+\): M+H\(^+\)).

\(^1\)H-NMR (400 MHz, DMSO-d\(_6\)): \(\delta \) [ppm] = 1.27 (t, 3H), 1.31 (t, 3H), 2.77 (q, 2H), 2.97 (q, 2H), 6.74 (s, 1H), 7.09 (t, 1H), 7.34 (t, 2H), 8.22 (m, 2H), 11.52 (s br, 1H).

Step 2: 5,7-Diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate

To a mixture of 5,7-diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-ol (4.17 g, 12.5 mmol, 1.0 eq) in 80 mL DCM was added triethylamine (2.61 mL, 18.7 mmol, 1.5 eq). The reaction mixture was cooled to 0 °C and trifluoromethanesulfonic anhydride (2.32 mL, 13.7 mmol, 1.1 eq) was added dropwise. The mixture was stirred for 10 min at 0 °C and then for 1 h at rt. After addition of DCM and water, the organic phase was washed with brine and was filtered through a silicon filter. The crude product was dried and gave 5.67 g of the title compound in 84% purity based on UPLC-MS (area-%) which corresponds to a yield of 96%.

UPLC-MS (Method 1): RT = 1.68 min; m/z = 400 (ES\(^+\): M+H\(^+\)).

Step 3: (4-{1-[((fe/t-Butoxycarbonyl)amino)cyclobutyl]phenyl}boronic acid [Int-2A]

To a solution of tert-butyl (1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborola n-2-yl)-phenyl]cyclobutyl)carbamate [Int-1 B] (5.63 g, 20.0 mmol, 1 eq) in 191 mL acetone is added ammonium acetate (7.38 g, 95.6 mmol, 4.78 eq). After the addition of sodium periodate (13.6 g, 63.6 mmol, 3.15 eq) the reaction mixture was stirred
overnight at rt. Then, the white suspension was treated with water. The remaining solid was isolated by filtration and treated with toluene that was directly removed by a rotary evaporator. This procedure was repeated three times. The remaining solid was dried in vacuo at 60 °C overnight to give 3.87 g (75%) of the title compound in 85% purity (UPLC, area-%).

UPLC-MS (Method 1): RT = 1.03 min; m/z = 292 (ES+: M+H)+.

Step 4: 5,7-Diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate

5,7-Diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate (500 mg, 1.05 mmol, 84% purity, 1 eq, see step 2), (4-[[[ie/t-butoxycarbonyl]amino]-cyclobutyl]phenyl)boronic acid [Int-2A, step 3] (483 mg, 1.58 mmol, 85% purity, 1.5 eq), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (94 mg, 0.12 mmol, 0.1 eq) and cesium carbonate (857 mg, 2.63 mmol, 2.5 eq) were dissolved in 8.9 mL DMF and heated under microwave irradiation to a temperature of 110 °C. After a hold time of 40 sec the reaction mixture was cooled to rt. The reaction was repeated four times in identical manner and afterwards the reaction mixtures of the four runs were combined. The solvent was removed by the use of a rotary evaporator and the resulting crude material was purified by preparative MPLC [Biotage Isolera: SNAP cartridge 100 g, hexane → hexane / ethyl acetate (4/1)] to give 406 mg (19 %) of the title compound in -60% purity (UPLC, area-%). The compound was forwarded to the next step without further purification.

UPLC-MS (Method 1): RT = 1.75 min; m/z = 497 (ES+: M+H)+.

Intermediate Example Int-3:
tert-Butyl (1-{4-[3-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl]phenyl}cyclobutyl)carbamate

Step 1: 3-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-ol

2-Cyano-2-phenylacetohydrazide [Int-1A] (1.00 g, 5.13 mmol, 1.0 eq) and IJJ.S.S.S-hexafluoropentaneâ”¢-dione (1.07 g, 5.13 mmol, 1.0 eq) were dissolved in 16.6 mL acidic acid and stirred for 3.5 h at 60 °C. The reaction mixture was allowed to stir at rt overnight. The precipitate was isolated by filtration. The solid was washed with hexane and dried to give 500 mg (27% yield) of the title compound.

UPLC-MS (Method 1): RT = 1.38 min; m/z = 348 (ES +: M+H) +.

Step 2: tert-Butyl (1-{4-[3-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl]phenyl}cyclobutyl)carbamate
To a mixture of 3-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-ol (500 mg, 1.44 mmol, 1.0 eq) in 9.3 ml DCM was added triethylamine (0.30 ml, 2.16 mmol, 1.5 eq). The reaction mixture was cooled to 0 °C and trifluoromethanesulfonic anhydride (0.27 ml, 1.58 mmol, 1.1 eq) was added dropwise. The mixture was stirred for 10 min at 0°C and then for 1 h at rt. After addition of DCM and water, the organic phase was washed with water and the volatile components were removed in vacuo. The crude product was purified by preparative MPLC [Biotage Isolera: SNAP cartridge 25 g, hexane → hexane / ethyl acetate (4/1)] to give 660 mg (91%) of 3-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate that was directly used as described in the following:

3-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl trifluoromethanesulfonate (230 mg, 0.46 mmol, 1 eq), (4-{1-[(tert-butoxycarbonyl)amino]cyclobutyl}-phenyl)boronic acid [Int-2A] (210 mg, 0.68 mmol, 85% purity, 1.5 eq), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (40.8 mg, 0.05 mmol, 0.11 eq) and cesium carbonate (371 mg, 1.14 mmol, 2.5 eq) were dissolved in 3.8 ml DMF and heated under microwave irradiation to a temperature of 110°C. After a hold time of 35 sec the reaction mixture was cooled to rt and the volatile components were removed in vacuo. The resulting crude material was purified by preparative MPLC [Biotage Isolera: SNAP cartridge 25 g, hexane → hexane / ethyl acetate (2/1)] to yield a sample of insufficient purity. This was forwarded to another preparative MPLC with adapted gradient [Biotage Isolera: SNAP cartridge 25 g, hexane → hexane / ethyl acetate (4/1)] to give 160 mg (55%) of title compound in 90% purity (UPLC, area-%).

UPLC-MS (Method 1): RT = 1.75 min; m/z (ES+) = 421 (M-fBu+2H)+, 494 (M+NH4)+.
Example 1: 1-[4-(5,7-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]cyclobutanamine

To a mixture of the carbamate Int-1 (650 mg, 1.39 mmol, 1.0 eq) in DCM (8.9 mL) and methanol (5.6 mL) was added a solution of 4 M hydrogen chloride in dioxane (6.94 mL, 27.7 mmol, 20.0 eq) at 0 °C. The reaction mixture was stirred overnight at rt and then poured onto ice. The reaction mixture was made alkaline with aqueous sodium hydroxide (2 N) and extracted with ethyl acetate. The solvent was removed by distillation and purification was achieved by column chromatography using preparative MPLC [Biotage Isolera: 25 g SNAP cartridge, hexane -> hexane / ethyl acetate 4/1)]. The product was finally crystallized from diisopropylether to give 212 mg (41% yield) of the title compound.

UPLC-MS (Method 1): RT = 1.02 min; m/z = 369 (ES+: M+1)+.

H-NMR (400 MHz, DMSO-d6): δ [ppm] = 0.93 (m, 1H), 1.25 (m, 1H), 1.36-1.50 (m, 2H), 1.67-1.82 (m, 5H), 1.96 (d, 3H), 6.00 (d, 1H), 6.41 - 6.56 (m, 3H), 6.57-6.66 (m, 4H), 6.75 (dt, 2H), (NH2 not assigned).

Example 2: 1-[4-(5,7-Diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]cyclobutanamine

To a mixture of the carbamate Int-2 (400 mg, 0.48 mmol, 60% purity, 1.0 eq) in DCM (2.4 mL) and methanol (2.0 mL) was added a solution of 4 M hydrogen chlo-
ride in dioxane (2.42 mL, 9.67 mmol, 20.0 eq). The reaction mixture was stirred for 3 h at rt and then poured onto ice. The reaction mixture was made alkaline with aqueous sodium hydroxide (2 N) and extracted with ethyl acetate. The solvent was removed by distillation under reduced pressure and purification was achieved by column chromatography using preparative MPLC [Biotage Isolera: SNAP cartridge KP-NH 55 g, hexane → hexane / ethyl acetate (4/1)]. The product was finally crystallized from diisopropylether to give 134 mg (69% yield) of the title compound.

**UPLC-MS** (Method 2): $RT = 1.60$ min; $m/z = 397$ (ES$^+$: M+1)$^+$.

$^1$H-NMR (400 MHz, DMSO-d$_6$): $\delta$ [ppm] = 1.23 (t, 3H), 1.37 (t, 3H), 1.62 (m, 1H), 1.87-2.14 (m, 3H), 2.29-2.42 (m, 3-4H), 2.76 (q, 2H), 3.13 (q, 2H), 6.92 (s, 1H), 7.25 (tt, 1H), 7.35 (t, 2H), 7.39-7.52 (m, 6H).

**Example 3:** 1-{4-[3-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrii midin-2-yl]phenyl)cyclobutanamine

![Chemical Structure](image)

To a mixture of the carbamate Int-3 (160 mg, 235 μmol, 1.0 eq) in DCM (1.5 mL) and methanol (1.0 mL) was added a solution of 4 M hydrogen chloride in dioxane (1.18 mL, 27.7 mmol, 20.0 eq) at 0 °C. The reaction mixture was stirred overnight at rt and then poured onto ice. The reaction mixture was made alkaline with aqueous sodium hydroxide (2 N) and extracted with ethyl acetate. The solvent was removed by distillation under reduced pressure and purification was achieved by column chromatography using preparative MPLC [Biotage Isolera: 25 g SNAP cartridge, hexane → hexane / ethyl acetate 4/1)]. The product was finally crystallized from diisopropylether. The filtration was conducted at 0 °C to give 40 mg (36% yield) of the title compound.

**MS:** $m/z = 460$ (ES$^+$: M-NH$_2$)$^+$.

**UPLC-MS** (Method 1): $RT = 1.24$ min; $m/z = 460$ (ES$^+$: M-NH$_2$)$^+$. 
Biological Investigations

The following assays can be used to illustrate the commercial utility of the compounds according to the present invention.

Examples were tested in selected biological assays one or more times. When tested more than once, data are reported as either average values or as median values, wherein

- the average value, also referred to as the arithmetic mean value, represents the sum of the values obtained divided by the number of times tested, and
- the median value represents the middle number of the group of values when ranked in ascending or descending order. If the number of values in the data set is odd, the median is the middle value. If the number of values in the data set is even, the median is the arithmetic mean of the two middle values.

Examples were synthesized one or more times. When synthesized more than once, data from biological assays represent average values or median values calculated utilizing data sets obtained from testing of one or more synthetic batch.

Biological Assay 1.0: \textbf{Akt1} kinase assay

\textbf{Akt1} inhibitory activity of compounds of the present invention was quantified employing the \textbf{Akt1} TR-FRET assay as described in the following paragraphs.

His-tagged human recombinant kinase full-length \textbf{Akt1} expressed in insect cells was purchased from Invitrogen (part number PV 3599). As substrate for the kinase reaction the biotinylated peptide biotln-Ahx-KKL-NRTLSFAEPG (C-terminus amidide form) was used which can be purchased e.g. from the company Biosynphan GmbH (Berlin-Buch, Germany).

For the assay 50 nL of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 \( \mu \)L of a solution of \textbf{Akt1} in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM \( \text{MgCl}_2 \), 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sig-
ma]) were added and the mixture was incubated for 15 min at 22°C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 µl of a solution of adenosine-tri-phosphate (ATP, 16.7 µM => final cone. in the 5 µl assay volume is 10 µM) and substrate (1.67 µM => final cone. in the 5 µl assay volume is 1 µM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22°C. The concentration of Akt1 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.05 ng/µl (final cone. in the 5 µl assay volume).

The reaction was stopped by the addition of 5 µl of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [CisBio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. # 35-001] and 0.75 nM LANCE Eu-W 1024 labeled anti-mouse IgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1 % (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5).

The resulting mixture was incubated 1 h at 22°C to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a HTRF reader, e.g. a Bystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor = 0 % inhibition, all other assay components but no enzyme = 100 % inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 μM to 1 nM (20 μM, 6.7 μM, 2.2 μM, 0.74 μM, 0.25 μM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100 fold cone. stock solutions by serial 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.

Biological Assay 2.0: Akt2 kinase assay
Akt2 inhibitory activity of compounds of the present invention was quantified employing the Akt2 TR-FRET assay as described in the following paragraphs.

His-tagged human recombinant kinase full-length Akt2 expressed in insect cells and activated by PDK1 was purchased from Invitrogen (part number PV 3975). As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-KKLNRTLSFAEPG (C-terminus in amide form) was used which can be purchased e.g. from the company Biosynthan GmbH (Berlin-Buch, Germany).

For the assay 50 nI of a 100 fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384 well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 µI of a solution of Akt2 in assay buffer [50 mM TRIS/HCl pH 7.5, 5 mM MgCb, 1 mM dithiothreitol, 0.02% (v/v) Triton X-100 (Sigma)] were added and the mixture was incubated for 15 min at 22°C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 µI of a solution of adenosine-tri-phosphate (ATP, 16.7 µM => final con. in the 5 µI assay volume is 10 µM) and substrate (1.67 µM => final con. in the 5 µI assay volume is 1 µM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22°C. The concentration of Akt2 in the assay was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.2 ng/µI (final con. in the 5 µI assay volume).

The reaction was stopped by the addition of 5 µI of a solution of HTRF detection reagents (200 nM streptavidine-XL665 [Cisbio] and 1.5 nM anti-phosho-Serine antibody [Millipore, cat. # 35-001] and 0.75 nM LANCE Eu-W 1024 labeled antimusIgG antibody [Perkin Elmer]) in an aqueous EDTA-solution (100 mM EDTA, 0.1 % (w/v) bovine serum albumin in 50 mM HEPES/NaOH pH 7.5).

The resulting mixture was incubated 1 h at 22°C to allow the binding of the biotinylated phosphorylated peptide to the streptavidine-XL665 and the antibodies.

Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the anti-mouse-IgG-Eu-Chelate to the streptavidine-XL665. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Ru-
bystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor = 0 % inhibition, all other assay components but no enzyme = 100 % inhibition). Normally test compound were tested on the same microtiter plate at 10 different concentrations in the range of 20 µM to 1 nM (20 µM, 6.7 µM, 2.2 µM, 0.74 µM, 0.25 µM, 82 nM, 27 nM, 9.2 nM, 3.1 nM and 1 nM, dilution series prepared before the assay at the level of the 100-fold con. stock solutions by seri- a1 1:3 dilutions) in duplicate values for each concentration and IC50 values were calculated by a 4 parameter fit using an in-house software.

Preferred compounds of the present invention show in either the Akt1 or Akt2 kinase assay: median IC50 < 5 µM or greater than 50% inhibition at 5 µM, more preferably, median IC50 < 0.5 µM or greater than 50% inhibition at 0.5 µM, even more preferably, median IC50 ≤ 0.1 µM or greater than 50% inhibition at 0.1 µM.

The following Table gives selected data for selected Examples of the present invention.

<table>
<thead>
<tr>
<th>Example</th>
<th>Akt1, median IC50, M</th>
<th>Akt2, median IC50, M</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.6E-6</td>
<td>4.6E-7</td>
</tr>
<tr>
<td>2</td>
<td>4.1E-7</td>
<td>4.1E-7</td>
</tr>
<tr>
<td>3</td>
<td>3.2E-7</td>
<td>8.6E-7</td>
</tr>
</tbody>
</table>

Cellular Assays 3.0: p-AKT1/2/3-S473, -T308, and p-4E-BP1-T70 assays
The molecular mechanism of action was investigated in a set of experiments to assess the inhibition of the PI3K-AKT-mTOR pathway in responsive cell lines such as KPL-4 breast tumour cell line (PIK3CA^H1047R, HER2^+/E and hormone independent). The phospho-substrates of PI3K-AKT-mTOR axis were used as the read-outs to reflect pathway inhibition. Cells were seeded at 60-80% confluency per well in 96-well cell culture plates. After overnight incubation at 37°C 5% CO2, cells were treated with compounds and vehicle at 37°C for 2 hours. Thereafter, cells were lysed in 150 µl lysis buffer and the levels of phospho-AKT at T308 and S473...
and P-4E-BP1 at T70 sites were determined with the corresponding AlphaScreen® SureFire® assay kits (Perkin Elmer: 4E-BP1 Assay Kit Cat # TRG4E2S 10K; Akt 1/2/3 p-Ser 473 #TGRA4S500 and Akt 1/2/3 p-Thr 308 #TGRA3S500 as well as IgG detection Kit #676061 7M) as described in the manuals. All measurements where at least done in duplicates and confirmed by independent repetition.

Alternatively pAKT-S473 was measured using the "Akt Duplex" of the MULTI-SPOT® Assay System (Fa. Meso Scale Discovery, Cat# N41 100B-1) following manufacturers instructions. Each assay used 20pg of protein extract and measured total AKT and p-AKT content simultaneously in one well. All measurements where at least done in duplicates and confirmed by independent repetition. Values for P-AKT are expressed as percentage of P-AKT level compared to total-AKT content of the extracts.

The following Table gives selected data for selected Examples of the present invention.

<table>
<thead>
<tr>
<th>Example</th>
<th>pAKT-S743 median IC50, M</th>
<th>P4EBP1-T70 median IC50, M</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.3E-7</td>
<td>1.8E-6</td>
</tr>
<tr>
<td>2</td>
<td>1.7E-6</td>
<td>3.7E-6</td>
</tr>
<tr>
<td>3</td>
<td>1.8E-6</td>
<td>3.3E-6</td>
</tr>
</tbody>
</table>

Biological Assay 4.0: Tumor cell proliferation assays

Compounds were tested in a cell-based assay that measures the capacity of the compounds to inhibit tumor cell proliferation following a 72h drug exposure. Cell viability is determined using CellTiter-Glow® (CTG, Promega, cat# G7571 /2/3).

The CellTiter-Glo® Luminescent Cell Viability Assay is a homogeneous method to determine the number of viable cells in culture. Detection is based on using the luciferase reaction to measure the amount of ATP from viable cells. The amount of ATP in cells correlates with cell viability. Within minutes after a loss of membrane integrity, cells lose the ability to synthesize ATP, and endogenous ATPases destroy any remaining ATP; thus the levels of ATP fall precipitously.

Cells were plated at 3000-5000 cells/well (depending on the cell lines) in 90 µL growth medium on MTPs (Corning; #3603, black plate, clear flat bottom). For each
cell line assayed, cells were plated onto a separate plate for determination of fluorescence at \( t = 0 \) hour and \( t = 72 \) hour time points. Following overnight incubation at 37 °C, chemiluminescence values for the \( t = 0 \) samples were determined after adding 10 \( \mu \)L medium and 100 \( \mu \)L CTG solution according to manufacture protocol. Plates for the \( t = 72 \) hour time points were treated with compounds diluted into growth medium at ten times final concentration added in 10 \( \mu \)L to the cell culture plate. Cells were then incubated for 72 hours at 37 °C. Chemiluminescence values for the \( t = 72 \) hour samples were determined. For data analysis, briefly, data from 24h plate where used to reflect 100% inhibition of growth ("Ci") and DMSO control for uninhibited growth ("CO") and analyzed using MTS software package for IC\(_{50}\) and Hill coefficient. Experiments were controlled using a reference compound as standard.

Preferred compounds of the present invention show in this assay an inhibition of cell growth of cell lines such as the KPL-4 breast cancer cell line and the MCF-7 breast tumour cell line (PIK3CA\(_{ES42K}^{ES45K}\), hormone dependent) with a median IC\(_{50}\) of <10 \( \mu \)M, more preferably, median IC\(_{50}\) ≤ 1 \( \mu \)M.

The following Table gives selected data for selected Examples of the present invention.

<table>
<thead>
<tr>
<th>Example</th>
<th>KPL-4 proliferation IC(_{50}), M</th>
<th>MCF7 proliferation IC(_{50}), M</th>
<th>KPL-4 median inhibition at 1.67 ( \mu )M (%)</th>
<th>MCF-7 median inhibition at 1.67 ( \mu )M (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.9E-6</td>
<td>1.8E-6</td>
<td>29.8</td>
<td>47.4</td>
</tr>
<tr>
<td>2</td>
<td>2.2E-6</td>
<td>2.0E-6</td>
<td>7.1</td>
<td>24.5</td>
</tr>
<tr>
<td>3</td>
<td>2.4E-6</td>
<td>2.0E-6</td>
<td>6.6</td>
<td>25.6</td>
</tr>
</tbody>
</table>

**Example 5.0 - Caco2 permeability assay**

Caco-2 cells (purchased from DSMZ Braunschweig, Germany) were seeded at a density of 4.5 \( \times \) 10\(^4\) cell per well on 24 well insert plates, 0.4 \( \mu \)m pore size, and grown for 15 days in DMEM medium supplemented with 10% fetal bovine serum, 1% GlutaMAX (100x, Gibco), 100 U/ml penicillin, 100\( \mu \)g/ml streptomycin (Gibco) and 1% non essential amino acids (100x). Cells were maintained at 37°C in a
humified 5% CO2 atmosphere. Medium was changed every 2-3 day. Before running the permeation assay, the culture medium was replaced by a FCS-free hepes-carbonate transport puffer (pH 7.2) For assessment of monolayer integrity the transepithelial electrical resistance (TEER) was measured. Test compounds were predissolved in DMSO and added either to the apical or basolateral compartment in final concentration of 2 μM. Before and after 2h incubation at 37°C samples were taken from both compartments. Analysis of compound content was done after precipitation with methanol by LC/MS/MS analysis. Permeability (Papp) was calculated in the apical to basolateral (A → B) and basolateral to apical (B → A) directions. The apparent permeability was calculated using following equation:

\[ \text{Papp} = \frac{(Vr/Po)(1/S)(P_{B-A})}{t} \]

Where \( V_r \) is the volume of medium in the receiver chamber, \( P_0 \) is the measured peak area of the test drug in the donor chamber at t-0, \( S \) the surface area of the monolayer, \( P_2 \) is the measured peak area of the test drug in the acceptor chamber after 2h of incubation, and \( t \) is the incubation time. The efflux ratio basolateral (B) to apical (A) was calculated by dividing the \( \text{Papp}_B \)-A by the \( \text{Papp}_A \)-B. In addition the compound recovery was calculated. As assay control reference compounds were analyzed in parallel.

Example 6.0 - in vivo rat pharmacokinetics
For in vivo pharmacokinetic experiments test compounds were administered to male Wistar rats intravenously at doses of 0.3 to 1 mg/kg and intragastral at doses of 0.6 to 10 mg/kg formulated as solutions using solubilizers such as PEG400 in well-tolerated amounts.

For pharmacokinetics after intravenous administration test compounds were given as i.v. bolus and blood samples were taken at 2 min, 8 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h after dosing. Depending on the expected half-life additional samples were taken at later time points (e.g. 48 h, 72 h). For pharmacokinetics after intragastral administration test compounds were given intragastral to fasted rats and blood samples were taken at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h and 24 h after dosing. Depending on the expected half-life additional samples were taken at later time points (e.g. 48 h, 72 h). Blood was
collected into Lithium-Heparintubes (Monovetten®, Sarstedt) and centrifuged for 15 min at 3000 rpm. An aliquot of 100 µi. from the supernatant (plasma) was taken and precipitated by addition of 400 µL cold acetonitrile and frozen at -20 °C over night. Samples were subsequently thawed and centrifuged at 3000 rpm, 4 °C for 20 minutes. ASi Quots of the supernatants were taken for analytical testing using an Agilent 1200 HPLC-system with LCMS/MS detection. PK parameters were calculated by non-compartmental analysis using a PK calculation software.

PK parameters derived from concentration-time profiles after i.v.: CLplasma: Total plasma clearance of test compound (in L/kg/h); CLblood: Total blood clearance of test compound: CLplasma* Cp/Cb (in L/kg/h) with Cp/Cb being the ratio of concentrations in plasma and blood. PK parameters calculated from concentration time profiles after i.g.: Cmax: Maximal plasma concentration (in mg/L); Cmaxnorm: Cmax divided by the administered dose (in kg/L); Tmax: Time point at which Cmax was observed (in h). Parameters calculated from both, i.v. and i.g. concentration-time profiles: AUCnorm: Area under the concentration-time curve from t=0h to infinity (extrapolated) divided by the administered dose (in kg*h/L); AUC(0-tlast)norm: Area under the concentration-time curve from t=0h to the last time point for which plasma concentrations could be measured divided by the administered dose (in kg*h/L); t1/2: terminal half-life (in h); F: oral bioavailability: AUCnorm after intragastral administration divided by AUCnorm after intravenous administration (in %).

The person skilled in the art will be aware of methods to show in vivo efficacy of anti-cancer compounds. By way of illustration, the following example describes methods of quantifying the in vivo efficacy in a mouse xenograft model. The skilled person will be able to apply such principles to derive models from alternative tumor material.

Example 7.0 In vivo xenograft mechanism of action study
To demonstrate that compounds act in tumours by the anticipated mode of action phosphorylation of the AKT protein was investigated in KPL-4 breast tumours treated once with 50 mg/kg compound.
To this extent KPL-4 human breast tumours were xenografted onto athymic nude mice. KPL-4 tumour cells were cultivated according to ATCC protocols in recommended media contained 10% FCS and harvested for transplantation in a subconfluent (70%) state. 3 x 10⁶ tumour cells suspended in 50% Matrigel were subcutaneously implanted into the inguinal region of female mice. Tumours were allowed to grow to the predetermined size of 60-80 mm². When the tumours were approximately in size, the animals were randomized to treatment and control groups (groups size: 9 animals) and treatment was started. Animals were treated once with 50 mg/kg compound or vehicle per oral administration (p.o.) carried out via a gastric tube. Treatment of each animal was based on individual body weight. At 2, 5 and 24 hours post treatment 3 animals each were sacrificed and the KPL-4 tumours excised. Tumour samples of approximately 5x5x5 mm were lysed on ice in MSD lysis buffer in the presence of protease and phosphatase inhibitors using Tissue Lyzer (Qiagen, Germany). The levels of p-AKT S473 in extracts from tumour tissue were analysed in an ELISA based assay. This assay is based on the "Akt Duplex" of the MULTI-SPOT® Assay System (Fa. Meso Scale Discovery, Cat# N41 100B-1) following manufacturers instructions. Each assay used 20µg of protein extract and measured total AKT and p-AKT content simultaneously in one well. All measurements where at least done in duplicates and confirmed by independent repetition.

Values for P-AKT are expressed as percentage of P-AKT level compared to total-AKT content of the extracts. Vehicle treated tumours were analyzed to determine the basal level of P-AKT in this model and used as a normalization control to determine the % P-AKT relative to vehicle levels.

Preferred compounds of the present invention show in this assay: relative to vehicle levels P-AKT < 30 % at 2 hours post treatment, more preferably at 5 hours post treatment, even more preferably at 24 hours post treatment.

Example 7.1 In vivo xenograft efficacy study
To determine the therapeutic efficacy and tolerability of compounds, tumour growth of KPL-4 breast tumours xenografted onto nude mice may be observed. Mice were treated either with vehicle or compounds. To this extent KPL-4 xenografts were established as described above. Tumours were allowed to grow to the predetermined size of 25 - 35 mm². When the tumours were approximately in size, the animals were randomized to treatment and control groups (groups size: 8 animals) and treatment was started. Treatment of each animal was based on individual body weight and oral administration (p.o.) was carried out via a gastric tube. The oral application volumes were 10 ml/kg for mice. Mice were treated once daily with 50 mg/kg compounds. Tumour response was assessed by determination of the tumour area (product of the longest diameter and its perpendicular) using a calliper. The animal body weight was monitored as a measure for treatment-related toxicity. Measurement of tumour area and body weight were performed 2-3 times weekly. Statistical analysis was assessed using the SigmaStat software. A one way analysis of variance was performed, and differences to the control were compared by a pair-wise comparison procedure (Dunn's method). T/C ratios (Treatment/Control) were calculated with final tumour weights at study end.
Claims

1. A compound of formula (I)

\[
\begin{align*}
\text{in which} \\
R^1 & \text{ is hydrogen, a 1-6C-alkyl group,} \\
& \text{wherein said group being optionally substituted, one or more times,} \\
& \text{identically or differently, with a substituent selected from:} \\
& \text{hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, }-\text{NR}^7\text{R}^8, \\
& \text{cyano, } (=)0, -\text{C}(0)\text{NR}^7\text{R}^8, -\text{C}(0)\text{OR}^9, -\text{NH}2{\text{C}(0)}\text{R}^{10}, -\text{NH}(1-6C-alkyl)-0-(1-6C-alkyl), \\
R^2 & \text{ is hydrogen or a 1-6C-alkyl group} \\
& \text{wherein said group is optionally substituted, one or more times, identically or differently,} \\
& \text{with a substituent selected from:} \\
& \text{hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, }-\text{NR}^7\text{R}^8, \\
& \text{cyano, } -\text{C}(0)\text{NR}^7\text{R}^8, -\text{C}(0)\text{OR}^9, -\text{NH}2{\text{C}(0)}\text{R}^{10}, -\text{NH}(1-6C-alkyl)-0-(1-6C-alkyl), \\
R^3 & \text{ is hydrogen, 1-6C-alkyl which is optionally substituted one or more times} \\
& \text{with halogen,} \\
R^4 & \text{ is phenyl optionally substituted by 1-6C-alkyl, halogen, cyano,} \\
R^5 & \text{ is hydrogen, halogen,} \\
R^6 & \text{ is hydrogen, 1-6C-alkyl,} \\
X & \text{ is } -\text{CH}_2-, \\
Y & \text{ is } -\text{CH}_2-, -\text{CH(OH)}-, \\
R^7, R^8 & \text{ which can be the same or different, is hydrogen, hydroxy, 3-7C-cycloalkyl or} \\
& \text{a group selected from 1-4C-alkyl, 1-6C-alkoxy, wherein said group is op-}
\end{align*}
\]
tionally substituted, one or more times, identically or differently, with a substituent selected from:

- halogen, hydroxy, mono- or di-(1-4C-alkylamino), 1-4C-alkoxy, or 3-7C-cycloalkyl or,

R\textsuperscript{7} and R\textsuperscript{8} together with the nitrogen to which they are attached may also form a saturated or unsaturated 3-6C-heterocyclic ring, which is optionally substituted by (=0)

R\textsuperscript{9} is hydrogen, 1-6C-alkyl,

R\textsuperscript{10} is 1-4C-alkyl (optionally substituted in the same way of differently one or more times with halogen, hydroxy) or 3-7C-cycloalkyl, or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

2. The compound of formula (I) according to claim 1,

wherein

- R\textsuperscript{1} is hydrogen, a 1-6C-alkyl group, wherein said group being optionally substituted, one or more times with halogen,

- R\textsuperscript{2} is hydrogen,

- R\textsuperscript{3} is hydrogen, a 1-6C-alkyl group, wherein said group being optionally substituted, one or more times with halogen,

- R\textsuperscript{4} is phenyl optionally substituted by 1-6C-alkyl, halogen, cyano,

- R\textsuperscript{5} is hydrogen,

- R\textsuperscript{6} is hydrogen,

- X is \(-\text{CH}_2\),

- Y is \(-\text{CH}_2\), \(-\text{CH(OH)}\),

or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

3. The compound of formula (I) according to claim 1,

wherein
R is is hydrogen, a 1-3C-alkyl group, wherein said group being optionally substituted, one or more times with halogen,

R² is hydrogen,

R³ is hydrogen, a 1-3C-alkyl group, wherein said group being optionally substituted, one or more times with halogen,

R⁴ is phenyl

R⁵ is hydrogen,

R⁶ is hydrogen,

X is -CH₂-, or a N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

Y is -CH₂-, or a N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

4. The compound of formula (I) according to claim 1, wherein,

R¹ is hydrogen, 1-3C-alkyl optionally substituted with fluorine,

R² is hydrogen,

R³ is hydrogen or 1-3C-alkyl optionally substituted with fluorine,

R⁴ is phenyl,

R⁵ is hydrogen,

R⁶ is hydrogen,

X is -CH₂-, or a N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

Y is -CH₂-, or a N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.

5. Compounds of formula (I) according to claim 1, which is selected from the group consisting of:

1-[4-(5,7-Dimethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]cyclobutanamine,

1-[4-(5,7-Diethyl-3-phenylpyrazolo[1,5-a]pyrimidin-2-yl)phenyl]cyclobutanamine,

1-[4-(3-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl)phenyl]cyclo-
butanamine.

6. Use of a compound of general formula (I) according to any of claims 1 to 5 for the treatment or prophylaxis of diseases.

7. Use of a compound of general formula (I) according to claim 6, whereby the diseases are hyperproliferative diseases and/or disorders responsive to induction of apoptosis.

8. Use of a compound of general formula (I) according to according to claim 7, whereby the hyperproliferative diseases and/or disorders responsive to induction of apoptosis are benign or malignant neoplasia.

9. Use of a compound of general formula (I) according to according to claim 7, whereby the hyperproliferative diseases is cancer.

10. Use of a compound of general formula (I) according to according to claim 9, whereby the cancer disease is breast cancer.

11. A pharmaceutical composition comprising at least one compound of general formula (I) according to any of claims 1 to 5, together with at least one pharmaceutically acceptable auxiliary.

12. A composition according to claim 11 for the treatment of benign or malignant neoplasia.


14 A combination comprising one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 5, and one or more second active ingredients selected from chemotherapeutic anti-cancer agents and target-specific anti-cancer agents.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
C07D487/04 A61K31/519
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category" Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
A wo 2010/114780 Al (MERCK SHARP & DOHME [US]; CHEN Qi [CN]; CUI MINGZIANG [CN]; HU BIN [CN] 7 October 2010 (2010-10-07) claims 1-7; examples 9.2-10. 12 1-14
A DATABASE CA [Online]
CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US;
2011,
SOMJEN, D. ET AL: "The effects of estrogen receptors .al pha. - and .beta. -specific agonists and antagonists on cell proliferation on and energy metabolism in human bone cell line", XP002694345,
retained from STN Database accessed on no. 2011:103295 abstract 1,3,14

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"A" document member of the same patent family

Date of the actual completion of the international search
22 March 2013

Date of mailing of the international search report
17/04/2013

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer
Rufet, Jacques

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&amp; FANG, JING ET AL: &quot;Computational Insights into Ligand Selectivity of Estrogen Receptors from Pharmacophore Modeling&quot;, MOLECULAR INFORMATICS, vol. 30, no. 6-7, 2011, pages 539-549, ISSN: 1868-1743</td>
<td>1, 6-14</td>
</tr>
<tr>
<td></td>
<td>wo 2011/055115 AI (ALMAC DISCOVERY LTD [GB]; BELL MARK PETER [GB]; O’DOWD COLIN RODERICK) 12 May 2011 (2011-05-12) cited in the application on claims 1-3, 20, 21</td>
<td>1, 6-14</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>WO 2010114780 A1</td>
<td>07-10-2010</td>
<td>EP 2413932 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012077810 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2010114780 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012309739 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2011055115 A1</td>
</tr>
</tbody>
</table>